U.S. patent application number 16/184580 was filed with the patent office on 2019-10-10 for formulations of an lsd1 inhibitor.
The applicant listed for this patent is Incyte Corporation. Invention is credited to Mei Li, Ying Liu, William L. Rocco, Tanvi Shah, Huifang Wu.
Application Number | 20190307736 16/184580 |
Document ID | / |
Family ID | 58668992 |
Filed Date | 2019-10-10 |
View All Diagrams
United States Patent
Application |
20190307736 |
Kind Code |
A1 |
Rocco; William L. ; et
al. |
October 10, 2019 |
FORMULATIONS OF AN LSD1 INHIBITOR
Abstract
The present application relates to pharmaceutical formulations
and dosage forms of a lysine specific demethylase-1 (LSD1)
inhibitor, or a pharmaceutically acceptable salt, solvate, or
hydrate thereof, including methods of preparation thereof, which
are useful in the treatment of LSD1 mediated diseases such as
cancer.
Inventors: |
Rocco; William L.; (Reading,
PA) ; Liu; Ying; (Exton, PA) ; Li; Mei;
(Newark, DE) ; Shah; Tanvi; (Philadelphia, PA)
; Wu; Huifang; (West Chester, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Incyte Corporation |
Wilmington |
DE |
US |
|
|
Family ID: |
58668992 |
Appl. No.: |
16/184580 |
Filed: |
November 8, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15493514 |
Apr 21, 2017 |
10166221 |
|
|
16184580 |
|
|
|
|
62326254 |
Apr 22, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/485 20130101;
A61P 35/02 20180101; A61P 35/00 20180101; A61P 43/00 20180101; A61K
9/2059 20130101; A61K 9/4833 20130101; A61K 9/4866 20130101; A61K
9/2009 20130101; A61K 9/4858 20130101; A61K 9/2018 20130101; A61K
9/2054 20130101; A61K 9/2013 20130101; A61K 9/0053 20130101; A61K
9/2095 20130101; A61K 9/2027 20130101; A61K 31/445 20130101 |
International
Class: |
A61K 31/445 20060101
A61K031/445; A61K 9/20 20060101 A61K009/20; A61K 9/00 20060101
A61K009/00; A61K 9/48 20060101 A61K009/48 |
Claims
1. A pharmaceutical formulation in solid oral dosage form
comprising: (a) an inhibitor of LSD1 which is Compound 1
di-tosylate salt of the formula: ##STR00019## or a solvate or
hydrate thereof, and (b) an organic acid.
2. The pharmaceutical formulation of claim 1, further comprising a
diluent.
3. The pharmaceutical formulation of claim 1, wherein the organic
acid is fumaric acid or citric acid.
4. The pharmaceutical formulation of claim 3, wherein the organic
acid is fumaric acid.
5. The pharmaceutical formulation of claim 4, comprising about 1 wt
% to about 50 wt % of fumaric acid.
6. The pharmaceutical formulation of claim 4, comprising about 1 wt
% to about 15 wt % of fumaric acid.
7. The pharmaceutical formulation of claim 4, comprising about 5 wt
% to about 15 wt % of fumaric acid.
8. The pharmaceutical formulation of claim 4, comprising about 9 wt
% to about 11 wt % of fumaric acid.
9. The pharmaceutical formulation of claim 4, comprising about 10
wt % of fumaric acid.
10. The pharmaceutical formulation of claim 1, comprising about 1
wt % to about 5 wt % of the LSD1 inhibitor.
11. The pharmaceutical formulation of claim 1, comprising about 2
wt % to about 4 wt % of the LSD1 inhibitor.
12. The pharmaceutical formulation of claim 1, comprising about 3
wt % of the LSD1 inhibitor.
13. The pharmaceutical formulation of claim 2, wherein the diluent
is lactose or mannitol.
14. The pharmaceutical formulation of claim 13, wherein the lactose
is lactose monohydrate or lactose-316 Fast Flo.RTM..
15. The pharmaceutical formulation of claim 14, comprising about 80
wt % to about 97 wt % of lactose monohydrate.
16. The pharmaceutical formulation of claim 14, comprising about 85
wt % to about 97 wt % of lactose monohydrate.
17. The pharmaceutical formulation of claim 1 further comprising a
lubricant, glidant, or both.
18. The pharmaceutical formulation of claim 17, wherein the
lubricant is sodium stearyl fumarate or stearic acid.
19. The pharmaceutical formulation of claim 18, wherein the
lubricant is sodium stearyl fumarate.
20. The pharmaceutical formulation of claim 19, comprising about 1
wt % to about 5 wt % of sodium stearyl fumarate.
21. The pharmaceutical formulation of claim 20, comprising about 2
wt % of sodium stearyl fumarate.
22. The pharmaceutical formulation of claim 18, wherein the
lubricant is stearic acid.
23. The pharmaceutical formulation of claim 22, comprising about 1
wt % to about 5 wt % of stearic acid.
24. The pharmaceutical formulation of claim 22, comprising about 2
wt % of stearic acid.
25. The pharmaceutical formulation of claim 17, wherein the glidant
is colloidal silica.
26. A pharmaceutical formulation comprising: (a)
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt
(Compound 1 di-tosylate salt), or a solvate or hydrate thereof; (b)
fumaric acid; and (c) lactose or mannitol, or a solvate or hydrate
thereof.
27. (canceled)
28. The pharmaceutical formulation of claim 26 further comprising
sodium stearyl fumarate.
29. The pharmaceutical formulation of claim 26 further comprising
stearic acid.
30.-31. (canceled)
32. The pharmaceutical formulation of claim 1, further comprising a
disintegrant.
33. The pharmaceutical formulation of claim 32, wherein the
disintegrant is croscarmellose sodium, sodium starch glycolate or
crospovidone.
34. The pharmaceutical formulation of claim 1, wherein the Compound
1 di-tosylate salt, or hydrate or solvate thereof, is in
crystalline form.
35. The pharmaceutical formulation of claim 34, wherein the
crystalline form comprises Form I.
36. The pharmaceutical formulation of claim 34, wherein the
crystalline form comprises Form HI.
37. The pharmaceutical formulation of claim 1, wherein the dosage
form is a tablet or capsule.
38.-48. (canceled)
Description
FIELD OF THE INVENTION
[0001] This application relates to pharmaceutical formulations and
solid dosage forms of a lysine specific demethylase-1 (LSD1)
inhibitor, or a pharmaceutically acceptable salt, solvate, or
hydrate thereof, including methods of preparation thereof, which
are useful in the treatment of LSD1 mediated diseases such as
cancer.
BACKGROUND
[0002] Overexpression of lysine specific demethylase-1 (LSD1) is
frequently observed in many types of cancers, including bladder
cancer, NSCLC, breast carcinomas, ovary cancer, glioma, colorectal
cancer, sarcoma including chondrosarcoma, Ewing's sarcoma,
osteosarcoma, and rhabdomyosarcoma, neuroblastoma, prostate cancer,
esophageal squamous cell carcinoma, and papillary thyroid
carcinoma. Notably, studies found over-expression of LSD1 was
significantly associated with clinically aggressive cancers, for
example, recurrent prostate cancer, NSCLC, glioma, breast, colon
cancer, ovary cancer, esophageal squamous cell carcinoma, and
neuroblastoma. In these studies, either knockdown of LSD1
expression or treatment with small molecular inhibitors of LSD1
resulted in decreased cancer cell proliferation and/or induction of
apoptosis. See, e.g., Hayami, S., et al., Overexpression of LSD1
contributes to human carcinogenesis through chromatin regulation in
various cancers. Int J Cancer, 2011. 128(3): p. 574-86; Lv, T., et
al., Over-expression of LSD1 promotes proliferation, migration and
invasion in non-small cell lung cancer. PLoS One, 2012. 7(4): p.
e35065; Serce, N., et al., Elevated expression of LSD1
(Lysine-specific demethylase 1) during tumour progression from
pre-invasive to invasive ductal carcinoma of the breast. BMC Clin
Pathol, 2012. 12: p. 13; Lim, S., et al., Lysine-specific
demethylase 1 (LSD1) is highly expressed in ER-negative breast
cancers and a biomarker predicting aggressive biology.
Carcinogenesis, 2010. 31(3): p. 512-20; Konovalov, S. and I.
Garcia-Bassets, Analysis of the levels of lysine-specific
demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects
of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian
Res, 2013. 6(1): p. 75; Sareddy, G. R., et al., KDM1 is a novel
therapeutic target for the treatment of gliomas. Oncotarget, 2013.
4(1): p. 18-28; Ding, J., et al., LSD1-mediated epigenetic
modification contributes to proliferation and metastasis of colon
cancer. Br J Cancer, 2013. 109(4): p. 994-1003; Bennani-Baiti, I.
M., et al., Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110)
is expressed and is an epigenetic drug target in chondrosarcoma,
Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol,
2012. 43(8): p. 1300-7; Schulte, J. H., et al., Lysine-specific
demethylase 1 is strongly expressed in poorly differentiated
neuroblastoma: implications for therapy. Cancer Res, 2009. 69(5):
p. 2065-71; Crea, F., et al., The emerging role of histone lysine
demethylases in prostate cancer. Mol Cancer, 2012. 11: p. 52;
Suikki, H. E., et al., Genetic alterations and changes in
expression of histone demethylases in prostate cancer. Prostate,
2010. 70(8): p. 889-98; Yu, Y., et al., High expression of
lysine-specific demethylase 1 correlates with poor prognosis of
patients with esophageal squamous cell carcinoma. Biochem Biophys
Res Commun, 2013. 437(2): p. 192-8; Kong, L., et al.,
Immunohistochemical expression of RBP2 and LSD1 in papillary
thyroid carcinoma. Rom J Morphol Embryol, 2013. 54(3): p.
499-503.
[0003] Inhibitors of LSD1 are currently being developed for the
treatment of cancer. For example, the molecule
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid (Compound 1) and other
small molecule inhibitors of LSD1 are reported in e.g., US
Publication Nos.: 2015-0225394, 2015-0225375, 2015-0225401,
2015-0225379, 2016-0009720, 2016-0009711, 2016-0009712, and
2016-0009721. Accordingly, there is a need for new formulations and
dosage forms of LSD1-inhibitors. The present invention is directed
toward this end.
SUMMARY OF THE INVENTION
[0004] The present invention is directed to, inter alia, a
pharmaceutical formulation comprising
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt
(Compound 1 di-tosylate salt), or a solvate or hydrate thereof, and
an organic acid.
[0005] The present invention is further directed to a dosage form
comprising a pharmaceutical formulation provided herein.
[0006] The present invention is further directed to a method of
treating a disease associated with LSD1 activity comprising
administering to a patient in need thereof a therapeutically
effective amount of a pharmaceutical formulation or a dosage form
provided herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 shows an X-ray powder diffraction (XRPD) pattern of
Compound 1 di-tosylate salt, Form I.
[0008] FIG. 2 shows a DSC thermogram of Compound 1 di-tosylate
salt, Form I.
[0009] FIG. 3 shows a TGA thermogram of Compound 1 di-tosylate
salt, Form I.
[0010] FIG. 4 shows an XRPD pattern of Compound 1 di-tosylate salt,
Form HI.
[0011] FIG. 5 shows a DSC thermogram of Compound 1 di-tosylate
salt, Form HI.
[0012] FIG. 6 shows a TGA thermogram of Compound 1 di-tosylate
salt, Form HI.
[0013] FIG. 7 shows an XRPD pattern of Compound 1 di-tosylate salt,
Form HII.
[0014] FIG. 8 shows a DSC thermogram of Compound 1 di-tosylate
salt, Form HII.
[0015] FIG. 9 shows a TGA thermogram of Compound 1 di-tosylate
salt, Form HII.
[0016] FIG. 10 shows an XRPD pattern of Compound 1 di-tosylate
salt, Form HIII.
[0017] FIG. 11 shows a DSC thermogram of Compound 1 di-tosylate
salt, Form HIII.
[0018] FIG. 12 shows a TGA thermogram of Compound 1 di-tosylate
salt, Form HIII.
[0019] FIG. 13 shows an XRPD pattern of Compound 1 di-tosylate
salt, Form DH.
[0020] FIG. 14 shows a DSC thermogram of Compound 1 di-tosylate
salt, Form DH.
[0021] FIG. 15 shows a TGA thermogram of Compound 1 di-tosylate
salt, Form DH.
[0022] FIG. 16 shows a DVS adsorption-desorption isotherm of
Compound 1 di-tosylate salt, Form I.
[0023] FIG. 17 shows a DVS adsorption-desorption isotherm of
Compound 1 di-tosylate salt, Form HI.
[0024] FIG. 18 shows a DVS adsorption-desorption isotherm of
Compound 1 di-tosylate salt, Form DH.
DETAILED DESCRIPTION
[0025] The present invention relates to pharmaceutical compositions
(or formulations) and dosage forms of Compound 1 di-tosylate salt
or a hydrate or solvate having improved stability. In particular,
the formulations and dosage forms of the present invention help
increase the stability of Compound 1 di-tosylate salt under ambient
conditions. Inclusion of an organic acid, such as fumaric acid,
advantageously reduces degradation of Compound 1 di-tosylate salt.
Additionally, use of a diluent, such as lactose (e.g., lactose
monohydrate) can provide a further stabilizing advantage.
[0026] Formulations
[0027] The present invention provides, inter alia, a pharmaceutical
formulation in solid oral dosage form comprising:
[0028] (a) an inhibitor of LSD1 which is Compound 1 di-tosylate
salt, or a solvate or hydrate thereof, and
[0029] (b) an organic acid.
[0030] Compound 1 refers to
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid having the formula:
##STR00001##
[0031] Compound 1 di-tosylate salt refers to
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate), which is shown below and is also
referred to as "Compound 1 bis-p-toluenesulfonic acid," "Compound 1
bis-p-toluenesulfonic acid salt," "Compound 1 di-p-toluenesulfonic
acid," "Compound 1 di-p-toluenesulfonic acid salt," "Compound 1
bis(4-methylbenzenesulfonate)," or
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt.
##STR00002##
[0032] Compound 1 can be prepared according to the procedures in US
Publication No. 2015/0225401, which is incorporated by reference in
its entirety. Compound 1 di-tosylate salt and various crystalline
forms can be prepared according to the procedures in U.S.
Provisional Application 62/204,105 and US Publication 2017/0044101,
each of which is incorporated by reference in its entirety. See
also e.g., Examples 6-7.
[0033] In some embodiments, Compound 1 di-tosylate salt used herein
is in Form I. In other embodiments, Compound 1 di-tosylate salt is
a hydrate, such as Form HI. Both Form I and Form HI are disclosed
in US Patent Publication No. 2017/0044101. The term "hydrate," as
used herein, is meant to refer to a solid form of Compound 1
di-tosylate salt that includes water. The water in a hydrate can be
present in a stoichiometric amount with respect to the amount of
salt in the solid, or can be present in varying amounts, such as
can be found in connection with channel hydrates. In some
embodiments, Compound 1 di-tosylate salt is a mono-hydrate (e.g.,
the molar ratio of the salt to water is about 1:1). In some
embodiments, Compound 1 di-tosylate salt is a di-hydrate (e.g., the
molar ratio of the salt to water is about 1:2). In some
embodiments, Compound 1 di-tosylate salt is a hemi-hydrate (e.g.,
the molar ratio of the salt to water is about 2:1). In some
embodiments, Compound 1 di-tosylate salt has one or more molecules
of water per molecule of salt.
[0034] Compound 1 di-tosylate salt can also be in a solvated form.
The term "solvate" means a solid form that includes solvent
molecules with Compound 1 di-tosylate salt. The solvent can be an
organic compound, an inorganic compound, or a mixture of both. Some
examples of solvents include, methanol, ethanol,
N,N-dimethylformamide, tetrahydrofuran, and dimethylsulfoxide. A
solvate where the solvent is water is generally referred to as a
"hydrate" or "hydrated form."
[0035] In some embodiments, the present invention provides a
pharmaceutical formulation comprising:
[0036] (a) an inhibitor of LSD1 which is Compound 1 di-tosylate
salt, or a solvate or hydrate thereof,
[0037] (b) an organic acid, and
[0038] (c) a diluent.
[0039] In certain embodiments, the pharmaceutical formulation
provided herein includes Compound 1 di-tosylate salt, or a solvate
or hydrate thereof, an organic acid, a diluent and a lubricant.
[0040] In some embodiments, the pharmaceutical formulation provided
herein can further include a glidant, a binder, a disintegrant, or
a combination thereof.
[0041] In some embodiments, the pharmaceutical formulation
comprises about 0.5 wt % to about 25 wt % or about 1 wt % to about
10 wt % of Compound 1 di-tosylate salt. In some embodiments, the
pharmaceutical formulation comprises about 1 wt % to about 10 wt %
of Compound 1 di-tosylate salt. In some embodiments, the
pharmaceutical formulation comprises about 1 wt % to about 5 wt %
of Compound 1 di-tosylate salt. In some embodiments, the
pharmaceutical formulation comprises about 2 wt % to about 4 wt %
of Compound 1 di-tosylate salt. In some embodiments, the
pharmaceutical formulation comprises about 1 wt %, about 2 wt %,
about 2.5 wt %, about 3 wt %, about 3.5 wt %, about 4 wt %, about
4.5 wt %, or about 5 wt % of Compound 1 di-tosylate salt. In some
embodiments, the pharmaceutical formulation comprises about 3 wt %
of Compound 1 di-tosylate salt. In some embodiments, the
pharmaceutical formulation includes about 2.5 wt % of Compound 1
di-tosylate salt.
[0042] Compound 1 di-tosylate salt, alone or together with
pharmaceutical excipients, can degrade to form impurities. One
impurity that may be formed is Compound 2, which is
14(4-(aminomethyl)-4-(methoxymethyl)piperidin-1-yl)methyl)cyclobutane-1-c-
arboxylic acid and has the following structure:
##STR00003##
[0043] Another impurity that may be formed is Compound 3, which is
phenylpropyl aldehyde having the following structure:
##STR00004##
[0044] The formulations and dosage forms provided herein can have
less than about 20%, less than about 15%, less than about 10%, less
than about 5%, less than about 4%, less than about 3%, less than
about 2%, less than about 1%, less than about 0.5%, or less than
about 0.1% by weight of Compound 2. In some embodiments, the
pharmaceutical formulations provided herein have less than about 2
wt % of Compound 2 as an impurity after exposure to about
25.degree. C. and about 60% RH (relative humidity) for about 2
weeks. In some embodiments, the pharmaceutical formulation provided
herein have less than about 25 wt %, less than about 20 wt %, less
than about 10 wt %, less than about 5 wt %, less than about 1 wt %,
or less than about 0.1 wt %, of Compound 2 as an impurity after
exposure to about 40.degree. C. and about 75% RH for about 2 weeks.
In some embodiments, the pharmaceutical formulations provided
herein have less than about 1 wt % of Compound 2 as an impurity
after exposure to about 25.degree. C. and about 60% RH (relative
humidity) for about 1 month. In some embodiments, the
pharmaceutical formulation provided herein have less than about 2
wt % or less than about 1 wt % of Compound 2 as an impurity after
exposure to about 40.degree. C. and about 75% RH for about 1
month.
[0045] The formulations of the invention include an organic acid
which provides a stabilizing effect. In particular, the organic
acid can inhibit the degradation of Compound 1 di-tosylate salt and
prevent the formation of Compound 2 and other impurities. Exemplary
organic acids include, but are not limited to, ascorbic acid,
citric acid, fumaric acid, lactic acid, maleic acid, malic acid,
sorbic acid, succinic acid, tartaric acid and hydrates or solvates
thereof. The organic acid in the formulation can be from about 1%
and to about 50%, about 1% to about 20%, about 1% to about 15%,
about 5% to about 15%, about 8% to about 12%, about 9% to about 11%
or about 10% by weight. For example, the organic acid in the
formulation can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25,
30, 35, 40, 45 or 50% by weight. In some embodiments, the organic
acid is fumaric acid or citric acid. In some embodiments, the
organic acid is fumaric acid. In some embodiments, the organic acid
is citric acid (e.g., citric acid monohydrate). While not wishing
to be bound by theory, it is believed that the presence of an
organic acid can create a localized pH within the pharmaceutical
formulations and/or dosage form that reduces the rate of
degradation.
[0046] In some embodiments, the pharmaceutical formulation
comprises about 1 wt % to about 50 wt %, about 1 wt % to about 40
wt %, about 1 wt % to about 30 wt %, about 1 wt % to about 25 wt %,
about 1 wt % to about 20 wt %, about 1 wt % to about 10 wt %, or
about 1 wt % to about 5 wt % of fumaric acid. In some embodiments,
the pharmaceutical formulation comprises about 1 wt % to about 50
wt % of fumaric acid. In some embodiments, the pharmaceutical
formulation comprises about 1 wt % to about 20 wt % of fumaric
acid. In some embodiments, the pharmaceutical formulation comprises
about 1 wt % to about 15 wt % of fumaric acid. In some embodiments,
the pharmaceutical formulation comprises about 5 wt % to about 15
wt % of fumaric acid. In some embodiments, the pharmaceutical
formulation comprises about 8 wt % to about 12 wt % or about 9 wt %
to about 11 wt % of fumaric acid. In some embodiments, the
pharmaceutical formulation comprises about 9 wt % to about 11 wt %
of fumaric acid. In some embodiments, the pharmaceutical
formulation comprises about 1 wt %, 2 wt %, 3 wt %, 4 wt %, 5 wt %,
about 6 wt %, about 7 wt %, about 8 wt %, about 9 wt %, about 10 wt
%, about 11 wt %, about 12 wt %, about 13 wt %, about 14 wt %,
about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about
35 wt %, about 40 wt %, about 45 wt %, or about 50 wt % of fumaric
acid. In some embodiments, the pharmaceutical formulation comprises
about 10 wt % of fumaric acid.
[0047] The diluent present in certain formulations of the invention
helps prevent degradation of Compound 1 di-tosylate salt. Exemplary
diluents include, but are not limited to, lactose, lactose
monohydrate, spray-dried monohydrate lactose, lactose-316 Fast
Flo.RTM., mannitol, microcrystalline cellulose, acidified
cellulose, starch 1500, prosolve MCC, and colloidal silica. In
certain instances, the diluents include lactose, lactose
monohydrate, spray-dried lactose monohydrate, lactose-316 Fast
Flo.RTM., mannitol and acidified cellulose. The diluent in the
formulation can be from about 5% to about 97% by weight. For
example, the diluent in the formulation can be about 5, about 10,
about 15, about 20, about 25, about 30, about 35, about 40, about
45, about 50, about 55, about 60, about 65, about 70, about 75,
about 80, about 85, about 90, about 95, about 96, or about 97% by
weight. In some embodiments, the diluent is lactose or mannitol. In
some embodiments, the diluent is lactose. In some embodiments, the
lactose is lactose anhydrous or lactose monohydrate. The lactose
monohydrate used herein can be amorphous, crystalline or a mixture
thereof. In some embodiments, the diluent is spray-dried
monohydrate lactose or lactose-316 Fast Flo.RTM..
[0048] The pharmaceutical formulations provided herein can comprise
about 5 wt % to about 97 wt %, about 70 wt % to about 97 wt % or
about 75 wt % to about 97 wt % of lactose monohydrate. In some
embodiments, the pharmaceutical formulation comprises about 80 wt %
to about 97 wt % of lactose monohydrate. In some embodiments, the
pharmaceutical formulation comprises about 85 wt % to about 97 wt %
of lactose monohydrate. In some embodiments, the pharmaceutical
formulation comprises about 86 wt % of lactose monohydrate. In some
embodiments, the pharmaceutical formulation comprises about 96 wt %
of lactose monohydrate. The pharmaceutical formulation provided
herein can include about 5, about 10, about 15, about 20, about 25,
about 30, about 35, about 40, about 45, about 50, about 55, about
60, about 65, about 70, about 75, about 80, about 85, about 90,
about 95, about 96, or about 97% lactose monohydrate by weight.
[0049] Other diluents can be present in the formulations of the
invention, for example, in an amount of 0 to about 85% by weight.
In some embodiments, the formulation has about 50 to about 80%,
about 55 to about 75%, or about 60 to about 70% by weight of
filler. Non-limiting examples of other diluents include
microcrystalline cellulose, starch 1500, and lactose anhydrous, or
combinations thereof.
[0050] In some embodiments, the formulations of the invention
include a lubricant. Lubricants can be present in the formulations
and dosage forms of the invention in an amount of about 0 to about
10% by weight. Non-limiting examples of lubricants include
magnesium stearate, stearic acid (stearin), hydrogenated oil,
polyethylene glycol, sodium stearyl fumarate, and glyceryl
behenate. In some embodiments, the lubricant is sodium stearyl
fumarate or stearic acid. In some embodiments, the lubricant is
sodium stearyl fumarate. In some embodiments, the lubricant is
stearic acid.
[0051] The pharmaceutical formulation can comprise about 1 wt % to
about 10 wt % of lubricant (e.g., sodium stearyl fumarate). In some
embodiments, the pharmaceutical formulation comprises about 1 wt %
to about 5 wt % of lubricant (e.g., sodium stearyl fumarate). In
some embodiments, the pharmaceutical formulation comprises about 1
wt % to about 3 wt % of lubricant (e.g., sodium stearyl fumarate).
In some embodiments, the pharmaceutical formulation comprises about
1 wt %, about 2 wt % about 3 wt %, about 4 wt %, or about 5 wt % of
lubricant (e.g., sodium stearyl fumarate). In some embodiments, the
pharmaceutical formulation comprises about 2 wt % of lubricant
(e.g., sodium stearyl fumarate). In some embodiments, the
pharmaceutical formulation comprises about 1 wt % to about 5 wt %
of stearic acid. In other embodiments, the pharmaceutical
formulation comprises about 2 wt % of stearic acid. In certain
embodiments, the lubricant in the formulation can be from about
0.1% to about 3% by weight. For example, the lubricant can be about
0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%,
about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about
1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%,
about 1.8%, about 1.9%, about 2%, about 2.5% or about 3% by
weight.
[0052] In some embodiments, the formulations of the invention
include a glidant. Glidants can be present in the formulations and
dosage forms of the invention in an amount of about 0 to about 5%
by weight. Non-limiting examples of glidants include talc,
colloidal silica (colloidal silicon dioxide), and cornstarch. In
some embodiments, the glidant is colloidal silica.
[0053] In some embodiments, the formulations of the invention
include a disintegrant. Disintegrants can be present in the dosage
forms of the invention in an amount of about 0 to about 10% by
weight. Non-limiting examples of disintegrants include
croscarmellose sodium, crospovidone, starch, cellulose, and low
substituted hydroxypropyl cellulose. In some embodimetns, the
disintegrant is croscarmellose sodium, sodium starch glycolate or
crospovidone.
[0054] In certain situations, a binder can be used in the
formulation. Exemplary binder includes polyvinyl pyrrolidone.
[0055] In some embodiments, film-coating agents can be present in
an amount of 0 to about 5% by weight. Non-limiting illustrative
examples of film-coating agents include hypromellose or polyvinyl
alcohol based coating with titanium dioxide, talc and optionally
colorants available in several commercially available complete
coating systems.
[0056] In some embodiments, where for example the formulations and
dosage forms of the invention are intended for sustained-release
dosage forms, a sustained-release matrix former can be included.
Example sustained-release matrix formers include cellulosic ethers
such as hydroxypropyl methylcellulose (HPMC, hypromellose) which is
a high viscosity polymer. The sustained-release dosage forms of the
invention can include, for example, about 10 to about 30%, about 15
to about 25%, or about 18 to about 24% by weight of a
sustained-release matrix former.
[0057] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0058] (a) about 1 wt % to about 5 wt % of Compound 1 di-tosylate
salt, or a solvate or hydrate thereof; and
[0059] (b) about 1 wt % to about 15 wt % of fumaric acid.
[0060] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0061] (a) about 3 wt % of Compound 1 di-tosylate salt; and
[0062] (b) about 10 wt % to about 15 wt % of fumaric acid.
[0063] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0064] (a) Compound 1 di-tosylate salt, or a solvate or hydrate
thereof;
[0065] (b) fumaric acid; and
[0066] (c) lactose or mannitol, or a solvate or hydrate
thereof.
[0067] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0068] (a) Compound 1 di-tosylate salt, or a solvate or hydrate
thereof;
[0069] (b) fumaric acid; and
[0070] (c) lactose, or a solvate or hydrate thereof.
[0071] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0072] (a) about 1 wt % to about 5 wt % of Compound 1 di-tosylate
salt, or a solvate or hydrate thereof;
[0073] (b) about 1 wt % to about 15 wt % of fumaric acid; and
[0074] (c) about 80 wt % to about 97 wt % of lactose (e.g.,
monohydrate lactose).
[0075] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0076] (a) Compound 1 di-tosylate salt, or a solvate or hydrate
thereof;
[0077] (b) fumaric acid;
[0078] (c) lactose, or a solvate or hydrate thereof; and
[0079] (d) a lubricant.
[0080] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0081] (a) about 1 wt % to about 5 wt % of Compound 1 di-tosylate
salt, or a solvate or hydrate thereof;
[0082] (b) about 1 wt % to about 15 wt % of fumaric acid;
[0083] (c) about 80 wt % to about 97 wt % of monohydrate lactose;
and
[0084] (d) about 1 wt % to about 5 wt % of a lubricant (e.g.,
sodium stearyl fumarate).
[0085] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0086] (a) about 1 wt % to about 5 wt % of Compound 1 di-tosylate
salt, or a solvate or hydrate thereof;
[0087] (b) about 1 wt % to about 15 wt % of fumaric acid;
[0088] (c) about 80 wt % to about 97 wt % of monohydrate lactose;
and
[0089] (d) about 1 wt % to about 5 wt % of stearic acid.
[0090] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0091] (a) about 3 wt % of Compound 1 di-tosylate salt;
[0092] (b) about 10 wt % to about 15 wt % of fumaric acid;
[0093] (c) about 86 wt % of monohydrate lactose; and
[0094] (d) about 2 wt % of a lubricant (e.g., sodium stearyl
fumarate).
[0095] In some embodiments, provided herein is a pharmaceutical
formulation comprising:
[0096] (a) about 3 wt % of Compound 1 di-tosylate salt;
[0097] (b) about 10 wt % to about 15 wt % of fumaric acid;
[0098] (c) about 86 wt % of monohydrate lactose; and
[0099] (d) about 2 wt % of a stearic acid.
[0100] The pharmaceutical formulations in solid dosage forms
provided herein which are suitable for oral administration can be
prepared by blending
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}met-
hyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate
salt with and an organic acid. The pharmaceutical formulation
formed can be further compressed to form a tablet. In some
embodiments, the organic acid is fumaric acid. The pharmaceutical
formulations in solid dosage form provided herein which are
suitable for oral administration can be prepared by blending
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt with
an organic acid and one or more portions of a diluent. The
pharmaceutical formulation formed can be further compressed to form
a tablet. In some embodiments, the organic acid is fumaric acid and
the diluent is lactose monohydrate.
[0101] The pharmaceutical formulations in solid dosage form
provided herein which are suitable for oral administration can be
prepared by:
[0102] a) blending
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt with
one or more portions of a diluent to form a first homogeneous
mixture;
[0103] b) blending the first mixture with an organic acid to form a
second homogeneous mixture; and
[0104] c) blending the second mixture with a lubricant to form the
pharmaceutical formulation. The pharmaceutical formulation formed
can be further compressed to form a tablet. In some embodiments,
the organic acid is fumaric acid, the diluent is lactose
monohydrate and the lubricant is sodium stearyl fumarate or steric
acid.
[0105] Provided is another method for preparing the pharmaceutical
formulations described herein which are suitable for oral
administration. The method includes:
[0106] a) blending
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt, an
organic acid and one or more portions of a diluent to form a
homogeneous mixture;
[0107] b) blending the homogenous mixture with a lubricant to form
the pharmaceutical formulation.
[0108] The pharmaceutical formulation formed can be further
compressed to form a tablet. In some embodiments, the organic acid
is fumaric acid, the diluent is lactose monohydrate and the
lubricant is sodium stearyl fumarate or steric acid.
[0109] Provided is another method for preparing the pharmaceutical
formulations described herein which are suitable for oral
administration. The method includes:
[0110] a) blending an organic acid and a diluent to form a first
homogeneous mixture;
[0111] b) wet granulating the first mixture and drying to afford a
dried mixture;
[0112] c) blending the dried mixture with
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt to
form a second homogeneous mixture; and
[0113] d) blending the second mixture with a lubricant to form the
pharmaceutical formulation. The pharmaceutical formulation formed
can be further compressed to form a tablet. In some embodiments,
the organic acid is fumaric acid, the diluent is lactose
monohydrate and the lubricant is sodium stearyl fumarate or steric
acid.
[0114] Compound 1 di-tosylate salt, diluent such as lactose
monohydrate, organic acid such as fumaric acid or mixtures thereof
can be prescreened to a uniformed particle size, for example,
between 40 and 100 mesh prior to subject the each of the blending
steps in the process of making the pharmaceutical formulations or
tablets. In some embodiments, the particle size is 30, 40, 60, 70
or 80 mesh.
[0115] As used herein, the terms "blend," "bending," and "blended"
refer to combining or mixing different substance to obtain a
mixture. The resulting blended mixture can be homogeneous.
[0116] As used herein, the term "granulating" refers the process
where the powder particles are made into larger granules. Wet
granulation refers to when granules are formed by the addition of a
granulation liquid such as water to the mixture.
[0117] In some embodiments, the Compound 1 di-tosylate salt, or
hydrate or solvate thereof, is in crystalline form. Crystalline
forms of Compound 1 di-tosylate salt (e.g., Form I) are disclosed
in U.S. Provisional Application 62/204,105 and US Publication No.
US 20170044101, the entireties of these are incorporated by
reference. In some embodiments, the crystalline form comprises Form
I. See also e.g., Examples 6-7.
[0118] In some embodiments, Form I has an X-ray powder diffraction
pattern comprising one or more characteristic peaks selected from
about 3.6, about 4.9, about 6.2, about 7.7 and about 22.7 degrees
2-theta. In some embodiments, Form I has an X-ray powder
diffraction pattern further comprising one or more characteristic
peaks selected from about 8.9, about 10.0, about 11.5, about 14.3,
about 15.0, about 15.5, about 16.3, about 17.8, about 19.1, about
19.8, about 20.9, and about 22.2 degrees 2-theta, and combinations
thereof.
[0119] In some embodiments, Form I has at least one characteristic
XRPD peak, in terms of 2-theta, at about 3.6 degrees. In some
embodiments, Form I has at least one characteristic XRPD peak, in
terms of 2-theta, at about 4.9 degrees. In some embodiments, Form I
has at least one characteristic XRPD peak, in terms of 2-theta, at
about 6.2 degrees. In some embodiments, Form I has at least one
characteristic XRPD peak, in terms of 2-theta, at about 7.7
degrees. In some embodiments, Form I has at least one
characteristic XRPD peak, in terms of 2-theta, at about 22.7
degrees.
[0120] In some embodiments, Form I has at least one characteristic
XRPD peak, in terms of 2-theta, at about 4.9 or about 6.2 degrees.
In some embodiments, Form I has at least one characteristic XRPD
peak, in terms of 2-theta, at about 3.6, about 4.9, or about 6.2
degrees.
[0121] In some embodiments, Form I has two or more characteristic
XRPD peaks, in terms of 2-theta, selected from about 3.6, about
4.9, about 6.2, about 7.7 and about 22.7 degrees. In some
embodiments, Form I has two or more characteristic XRPD peaks, in
terms of 2-theta, selected from at about 3.6, about 4.9, about 6.2,
about 7.7, about 22.7, about 8.9, about 10.0, about 11.5, about
14.3, about 15.0, about 15.5, about 16.3, about 17.8, about 19.1,
about 19.8, about 20.9, and about 22.2 degrees.
[0122] In some embodiments, Form I has three or more characteristic
XRPD peaks, in terms of 2-theta, selected from about 3.6, about
4.9, about 6.2, about 7.7, about 22.7, about 8.9, about 10.0, about
11.5, about 14.3, about 15.0, about 15.5, about 16.3, about 17.8,
about 19.1, about 19.8, about 20.9, and about 22.2 degrees.
[0123] In some embodiments, Form I has four or more characteristic
XRPD peaks, in terms of 2-theta, selected from about 3.6, about
4.9, about 6.2, about 7.7, about 22.7, about 8.9, about 10.0, about
11.5, about 14.3, about 15.0, about 15.5, about 16.3, about 17.8,
about 19.1, about 19.8, about 20.9, and about 22.2 degrees.
[0124] In some embodiments, Form I has an X-ray powder diffraction
pattern comprising one or more characteristic peaks selected from
about 3.6, about 4.9, about 6.2, about 7.7, about 22.7, about 8.9,
about 10.0, about 11.5, about 14.3, about 15.0, about 15.5, about
16.3, about 17.8, about 19.1, about 19.8, about 20.9, and about
22.2 degrees 2-theta, and combinations thereof.
[0125] In some embodiments, Form I exhibits a differential scanning
calorimetry thermogram having an endothermic peak at a temperature
of about 103.degree. C. In some embodiments, Form I exhibits a
differential scanning calorimetry thermogram having an endotherm
with an onset temperature of about 95.degree. C. and a peak
temperature of about 103.degree. C. In some embodiments, Form I
exhibits a differential scanning calorimetry thermogram having an
endotherm with an onset temperature of about 94.6.degree. C. and a
peak temperature of about 103.1.degree. C. In some embodiments,
Form I has an endothermic peak (e.g., a melting point) at a
temperature of about 103.degree. C. In some embodiments, Form I has
an exothermic peak at a temperature about 187.degree. C. In some
embodiments, Form I has a melting point of about 103.1.degree.
C.
[0126] In some embodiments, Form I exhibits a DSC thermogram having
an endotherm with an onset temperature of about 95.degree. C., and
a peak temperature of about 103.degree. C.; and an X-ray powder
diffraction pattern comprising one or more characteristic peaks at
about 3.6, about 4.9, about 6.2, about 7.7, or about 22.7 degrees
2-theta.
[0127] In some embodiments, Form I exhibits a DSC thermogram having
an endothermic peak at about 103.degree. C.; and an X-ray powder
diffraction pattern comprising one or more characteristic peaks at
about 3.6, about 4.9, about 6.2, about 7.7, or about 22.7 degrees
2-theta. In some embodiments, Form I exhibits a differential
scanning calorimetry thermogram having an endotherm with an onset
temperature of about 94.6.degree. C. and a peak temperature of
about 103.1.degree. C.; and an X-ray powder diffraction pattern
comprising a characteristic peak at about 3.6, about 4.9, about
6.2, about 7.7, or about 22.7 degrees 2-theta.
[0128] In some embodiments, Form I exhibits a DSC thermogram having
an exothermic peak at about 187.degree. C.; and an X-ray powder
diffraction pattern comprising one or more characteristic peaks at
about 3.6, about 4.9, about 6.2, about 7.7, or about 22.7 degrees
2-theta.
[0129] The XRPD analysis carried out on Form I was obtained from
Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general
experimental procedures for XRPD were: (1) X-ray radiation from
copper at 1.054056 .ANG. with K.sub..beta. filter; (2) X-ray power
at 30 KV, 15 mA; and (3) the sample powder was dispersed on a
zero-background sample holder. The general measurement conditions
for XRPD were: Start Angle 3 degrees; Stop Angle 45 degrees;
Sampling 0.02 degrees; and Scan speed 2 degree/min. The XRPD data
are provided in Table 1.
TABLE-US-00001 TABLE 1 XRPD Data of Form I 2-Theta (.degree.)
Height H % 3.6 460 70 4.9 608 92.5 6.2 658 100 7.7 326 49.6 8.9 116
17.6 10.0 128 19.5 11.5 132 20.1 13.8 42 6.3 14.3 51 7.8 15.0 98
14.9 15.5 105 15.9 16.3 123 18.7 17.1 49 7.4 17.8 170 25.8 19.1 163
24.8 19.8 108 16.4 20.9 202 30.8 22.2 170 25.9 22.7 408 62 23.1 133
20.3 23.9 49 7.5 24.4 94 14.3 24.9 73 11 25.8 65 9.9 27.2 55 8.4
28.7 43 6.5 29.1 53 8.1 30.6 47 7.1 31.2 70 10.6 32.8 59 9 38.4 39
5.9 39.6 35 5.4 43.9 36 5.5
[0130] The DSC of Form I was obtained from TA Instruments
Differential Scanning calorimetry, Model Q200 with autosampler. The
DSC instrument conditions were as follows: 30-300.degree. C. at
10.degree. C./min; T.sub.zero aluminum sample pan and lid; and
nitrogen gas flow at 50 mL/min. The DSC thermogram revealed a major
endothermal event at an onset temperature of 94.6.degree. C. with a
peak temperature of 103.1.degree. C. which is believed to be the
melting of the compound.
[0131] The TGA of Form I was obtained using a TA Instrument
Thermogravimetric Analyzer, Model Q500. The general experimental
conditions for TGA were: ramp from 20.degree. C. to 600.degree. C.
at 20.degree. C./min; nitrogen purge, gas flow at 40 mL/min
followed by balance of the purge flow; sample purge flow at 60
mL/min; platinum sample pan. A weight loss of about 3.5% up to
150.degree. C. was observed and believed to be associated with the
loss of moisture and residual solvents. The compound started to
decompose significantly after 200.degree. C.
[0132] In some embodiments, the crystalline form comprises Form HI.
Experimental evidence shows that Form HI is a hydrated form.
[0133] In some embodiments, Form HI has an XRPD pattern comprising
a characteristic peak, in terms of 2-theta, at about 7.0 degrees.
In some embodiments, Form HI has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 10.4 degrees. In
some embodiments, Form HI has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 13.6 degrees. In
some embodiments, Form HI has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 15.5 degrees. In
some embodiments, Form HI has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 17.3 degrees. In
some embodiments, Form HI has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 22.2 degrees. In
some embodiments, Form HI has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 24.0
degrees.
[0134] In some embodiments, Form HI has an XRPD pattern comprising
two or more characteristic peaks, in terms of 2-theta, selected
from about 7.0, about 10.4, about 13.6, about 15.5, about 17.3,
about 22.2, and about 24.0 degrees. In some embodiments, Form HI
has an X-ray powder diffraction pattern comprising three or more
characteristic peaks, in terms of 2-theta, selected from about 7.0,
about 10.4, about 13.6, about 15.5, about 17.3, about 22.2, and
about 24.0 degrees.
[0135] In some embodiments, Form HI has an XRPD pattern comprising
one or more characteristic peaks, in terms of 2-theta, selected
from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6,
about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about
20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about
28.2 degrees.
[0136] In some embodiments, Form HI has an XRPD comprising two or
more characteristic peaks, in terms of 2-theta, selected from about
7.0, about 10.4, about 13.6, about 15.5, about 16.6, about 17.3,
about 18.7, about 19.8, about 20.2, about 20.5, about 20.8, about
21.7, about 22.2, about 23.1, about 24.0, and about 28.2
degrees.
[0137] In some embodiments, Form HI has an XRPD pattern comprising
three or more characteristic peaks, in terms of 2-theta, selected
from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6,
about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about
20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about
28.2 degrees.
[0138] In some embodiments, Form HI has an XRPD pattern comprising
four or more characteristic peaks, in terms of 2-theta, selected
from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6,
about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about
20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about
28.2 degrees.
[0139] In some embodiments, Form HI exhibits a differential
scanning calorimetry thermogram having an endotherm with an onset
temperature of about 74.degree. C. and a peak temperature of about
80.degree. C. In some embodiments, Form HI has an endothermic peak
(e.g., a dehydration event) at a temperature of about 80.degree.
C.
[0140] In some embodiments, Form HI exhibits a differential
scanning calorimetry thermogram having an endothermic peak at a
temperature of about 80.degree. C.; and an XRPD pattern comprising
a characteristic peak selected from about 7.0, about 15.5, and
about 17.3 degrees 2-theta. In some embodiments, Form HI exhibits a
differential scanning calorimetry thermogram having an endotherm
with an onset temperature of about 74.degree. C. and a peak
temperature of about 80.degree. C.; and an XRPD pattern comprising
a characteristic peak selected from about 7.0, about 15.5, and
about 17.3 degrees 2-theta.
[0141] In some embodiments, Form HI exhibits a differential
scanning calorimetry thermogram having an endothermic peak at a
temperature of about 80.degree. C.; and an XRPD pattern comprising
a characteristic peak selected from about 7.0, about 10.4, about
13.6, about 15.5, about 17.3, about 22.2, and about 24.0 degrees.
In some embodiments, Form HI exhibits a differential scanning
calorimetry thermogram having an endotherm with an onset
temperature of about 74.degree. C. and a peak temperature of about
80.degree. C.; and an XRPD pattern comprising a characteristic peak
selected from about 7.0, about 10.4, about 13.6, about 15.5, about
17.3, about 22.2, and about 24.0 degrees.
[0142] Form HI of Compound 1 di-tosylate salt was prepared during
the process of drying a wet sample of Compound 1 di-tosylate salt,
Form I, under ambient conditions. Form I slowly absorbed
atmospheric moisture and gradually changed to crystalline Form HI.
Under storage conditions of 25.degree. C./60% RH and 40.degree.
C./75% RH, Form I was also converted to Form HI. The XRPD of Form
HI was obtained from Bruker D2 PHASER X-ray Powder
[0143] Diffractometer (XRPD) instrument. The general experimental
procedures for XRPD were: (1) X-ray radiation from copper at
1.054056 .ANG. with K.sub..beta. filter and LYNXEYE.TM. detector;
(2) X-ray power at 30 KV, 10 mA; and (3) the sample powder was
dispersed on a zero-background sample holder. The general
measurement conditions for XRPD were: Start Angle 5 degrees; Stop
Angle 30 degrees; Sampling 0.015 degrees; and Scan speed 2
degree/min. The XRPD data are provided in Table 2.
TABLE-US-00002 TABLE 2 XRPD Data of Form HI 2-Theta (.degree.)
Height H % 7.0 4354 77.6 8.9 886 15.8 9.3 1185 21.1 10.4 3139 55.9
10.7 660 11.8 11.5 51 0.9 12.0 151 2.7 13.6 2036 36.3 14.1 491 8.7
14.4 124 2.2 15.5 4512 80.4 16.2 857 15.3 16.6 2374 42.3 17.3 4304
76.7 17.9 1242 22.1 18.7 2547 45.4 19.8 3854 68.7 20.2 3439 61.3
20.5 2144 38.2 20.8 4164 74.2 21.4 1389 24.8 21.7 2735 48.7 22.2
4344 77.4 23.1 2229 39.7 24.0 5611 100 24.7 126 2.2 25.3 786 14.0
25.5 1072 19.1 26.0 379 6.8 26.7 730 13.0 27.3 340 6.1 28.2 1649
29.4 28.8 246 4.4 29.2 144 2.6
[0144] The DSC of Form HI was obtained from TA Instruments
Differential Scanning calorimetry, Model Q2000 with autosampler.
The DSC instrument conditions were as follows: 25-150.degree. C. at
10.degree. C./min; T.sub.zero aluminum sample pan and lid; and
nitrogen gas flow at 50 mL/min. The DSC thermogram revealed a major
endothermal event at an onset temperature of 73.5.degree. C. with a
peak temperature of 79.8.degree. C. which is believed to a
dehydration event.
[0145] The TGA of Form HI was obtained using a PerkinElmer
Thermogravimetric Analyzer, Model Pyris 1. The general experimental
conditions for TGA were: ramp from 25.degree. C. to 200.degree. C.
at 10.degree. C./min; nitrogen purge gas flow at 60 mL/min; ceramic
crucible sample holder. A weight loss of about 5.3% up to
110.degree. C. was observed and believed to be associated mostly
with the loss of water.
[0146] In some embodiments, the crystalline form comprises Form
HII. Experimental evidence shows that Form HII is a hydrated
form.
[0147] In some embodiments, Form HII has an XRPD pattern comprising
a characteristic peak, in terms of 2-theta, at about 8.7 degrees.
In some embodiments, Form HII has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 10.1 degrees. In
some embodiments, Form HII has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 14.8 degrees. In
some embodiments, Form HII has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 21.3 degrees. In
some embodiments, Form HII has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 22.0 degrees. In
some embodiments, Form HII has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 22.7 degrees. In
some embodiments, Form HII has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 24.3
degrees.
[0148] In some embodiments, Form HII has an XRPD pattern comprising
two or more characteristic peaks, in terms of 2-theta, selected
from about 8.7, about 10.1, about 14.8, about 21.3, about 22.0,
about 22.7, and about 24.3 degrees 2-theta.
[0149] In some embodiments, Form HII has an XRPD pattern comprising
three or more characteristic peaks, in terms of 2-theta, selected
from about 8.7, about 10.1, about 14.8, about 21.3, about 22.0,
about 22.7, and about 24.3 degrees 2-theta.
[0150] In some embodiments, Form HII exhibits a differential
scanning calorimetry thermogram having an endothermic peak at a
temperature of about 52.degree. C.
[0151] In some embodiments, Form HII exhibits a differential
scanning calorimetry thermogram having an endothermic peak at a
temperature of about 52.degree. C.; and an X-ray powder diffraction
pattern comprising a characteristic peak selected from about 8.7,
about 10.1, about 14.8, about 21.3, about 22.0, about 22.7, and
about 24.3 degrees 2-theta.
[0152] Form HII was prepared by slurring of Form I in water for 3
days at room temperature. The resulted suspension was filtered. The
residual solid was collected and air dried for 5-7 days at ambient
condition.
[0153] Form HII was characterized by XRPD. The XRPD was obtained
from Bruker D2 PHASER X-ray Powder Diffractometer instrument. The
general experimental procedures for XRPD are similar to those for
Form HI. The XRPD data are provided in Table 3.
TABLE-US-00003 TABLE 3 XRPD Data of Form HII 2-Theta (.degree.)
Height H % 6.5 902 21.6 6.9 1739 43.0 8.0 74.7 1.8 8.7 2372 56.9
10.1 4023 96.5 10.9 212 5.1 12.8 103 2.5 13.7 717 17.2 14.3 2944
70.6 14.8 3399 81.5 15.5 699 16.8 15.6 662 15.9 15.9 873 20.9 16.0
808 19.4 16.5 526 12.6 16.9 1215 29.1 17.4 2487 59.6 17.7 2644 63.4
18.2 2023 48.5 19.3 195 4.7 20.0 1888 45.3 20.5 3037 72.8 20.6 2694
64.6 21.3 3226 77.4 22.1 2317 55.6 22.0 3129 75.0 22.7 4170 100
23.2 1453 34.8 23.5 1263 30.3 24.3 3560 85.4 24.6 2153 51.6 25.1
804 19.3 25.4 792 19.0 26.1 594 14.2 27.1 817 19.6 27.6 184 4.4
28.4 2374 56.9 29.5 290 7.0
[0154] Form HII was characterized by DSC. The DSC was obtained from
TA Instruments Differential Scanning calorimetry, Model Q2000 with
autosampler. The DSC instrument conditions are similar to those for
Form HI. The DSC thermogram revealed a major endothermal event at
an onset temperature of 49.0.degree. C. with a peak temperature of
52.3.degree. C. which is believed to be the dehydration of the
compound.
[0155] Form HII was characterized by TGA. The TGA was obtained from
PerkinElmer Thermogravimetric Analyzer, Model Pyris 1. The general
experimental conditions for TGA are similar to those for Form HI. A
weight loss of about 11.3% up to 120.degree. C. was observed and is
believed to be associated mostly with the loss of water.
[0156] In some embodiments, the crystalline form comprises Form
HIII. Experimental evidence shows that Form HIII is a hydrated
form.
[0157] In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about 7.0
degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about 9.0
degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about 9.2
degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about
10.2 degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about
17.9 degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about
20.3 degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about
22.0 degrees. In some embodiments, Form HIII has an XRPD pattern
comprising a characteristic peak, in terms of 2-theta, at about
23.8 degrees.
[0158] In some embodiments, Form HIII has an XRPD pattern
comprising two or more characteristic peaks, in terms of 2-theta,
selected from about 7.0, about 9.0, about 9.2, about 10.2, about
17.9, about 20.3, about 22.0, and about 23.8 degrees.
[0159] In some embodiments, Form HIII has an XRPD pattern
comprising three or more characteristic peaks, in terms of 2-theta,
selected from about 7.0, about 9.0, about 9.2, about 10.2, about
17.9, about 20.3, about 22.0, and about 23.8 degrees 2-theta.
[0160] In some embodiments, Form HIII exhibits a differential
scanning calorimetry thermogram having an endothermic peak at a
temperature of about 67.degree. C. In some embodiments,
[0161] Form HIII further exhibits an endothermic peak at a
temperature of about 98.degree. C.
[0162] In some embodiments, Form HIII exhibits a differential
scanning calorimetry thermogram having endothermic peaks at
temperatures of about 67.degree. C. and about 98.degree. C.; and an
X-ray powder diffraction pattern comprising a characteristic peak
selected from about 7.0, about 9.0, about 9.2, about 10.2, about
17.9, about 20.3, about 22.0, and about 23.8 degrees 2-theta.
[0163] Form HIII was prepared by drying Form HI on Vapor Sorption
Analyzer (TA Instruments VTI-SA.sup.+) at 40.degree. C. with 0% RH
N.sub.2 for 3 h and then exposing it to humidity at about 30-50% RH
at 25.degree. C. for 1 day. Form HIII can change to Form HI when it
is further exposed to high humidity at about 60-85% RH.
[0164] Form HIII was characterized by XRPD. The XRPD was obtained
from Bruker D2 PHASER X-ray Powder Diffractometer (XRPD)
instrument. The general experimental procedures for XRPD are
similar to those for Form HI. The XRPD data are provided in Table
4.
TABLE-US-00004 TABLE 4 XRPD Data of Form HIII 2-Theta (.degree.)
Height H % 7.0 1719 31.2 8.6 86.6 1.6 9.0 2232 40.5 9.2 2435 44.1
10.2 3550 64.4 10.6 110 2.0 11.7 481 8.7 13.1 1671 30.3 13.5 99.6
1.8 13.9 150 2.7 14.3 269 4.9 15.0 1698 30.8 15.6 1398 25.3 16.2
742 13.4 16.3 443 8.0 17.1 1989 36.1 17.4 2147 38.9 17.9 2597 47.1
18.4 519 9.4 18.9 1756 31.8 19.8 475 8.6 20.3 4956 89.8 20.9 842
15.3 22.0 4791 86.9 22.5 736 13.3 22.9 635 11.5 23.4 603 10.9 23.5
826 15.0 23.8 5517 100 24.0 1063 19.3 24.6 453 8.2 25.2 849 15.4
25.5 580 10.5 26.2 778 14.1 26.5 854 15.5 27.5 603 10.9 28.1 515
9.3 28.9 2297 43.5 29.1 210 3.8 29.8 101 1.8
[0165] Form HIII was characterized by DSC. The DSC was obtained
from TA Instruments Differential Scanning calorimetry, Model Q2000
with autosampler. The DSC instrument conditions are similar to
those for Form HI. The DSC thermogram revealed two major
endothermal events. The first event appeared at an onset
temperature of 54.3.degree. C. with a peak temperature of
66.8.degree. C. which is believed to be the dehydration of the
compound. The second event appeared at an onset temperature of
92.6.degree. C. with a peak temperature of 98.4.degree. C. which is
believed to be the melting of the compound.
[0166] Form HIII was characterized by TGA. The TGA was obtained
from PerkinElmer Thermogravimetric Analyzer, Model Pyris 1. The
general experimental conditions for TGA are similar to those for
Form HI. A weight loss of about 4.8% up to 120.degree. C. was
observed and is believed to be associated mostly with the loss of
water.
[0167] In some embodiments, the crystalline form comprises Form
DH.
[0168] In some embodiments, Form DH has an XRPD pattern comprising
a characteristic peak, in terms of 2-theta, at about 7.5 degrees.
In some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 9.6 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 10.7 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 14.8 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 20.1 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 20.7 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 21.6 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 22.9 degrees. In
some embodiments, Form DH has an XRPD pattern comprising a
characteristic peak, in terms of 2-theta, at about 24.7
degrees.
[0169] In some embodiments, Form DH has an XRPD pattern comprising
two or more characteristic peaks, in terms of 2-theta, selected
from about 7.5, about 9.6, about 10.7, about 14.8, about 20.1,
about 20.7, about 21.6, about 22.9, and about 24.7 degrees
2-theta.
[0170] In some embodiments, Form DH has an XRPD pattern comprising
three or more characteristic peaks, in terms of 2-theta, selected
from about 7.5, about 9.6, about 10.7, about 14.8, about 20.1,
about 20.7, about 21.6, about 22.9, and about 24.7 degrees 2-theta.
In some embodiments, Form DH exhibits a differential scanning
calorimetry thermogram having an endothermic peak at a temperature
of about 98.degree. C.
[0171] In some embodiments, Form DH exhibits a differential
scanning calorimetry thermogram having an endothermic peak at a
temperature of about 98.degree. C.; and an X-ray powder diffraction
pattern comprising a characteristic peak selected from about 7.5,
about 9.6, about 10.7, about 14.8, about 20.1, about 20.7, about
21.6, about 22.9, and about 24.7 degrees 2-theta.
[0172] Form DH was prepared by drying Form HI on Vapor Sorption
Analyzer (TA Instruments VTI-SA.sup.+) at 25.degree. C. with 0% RH
N.sub.2 for 2 days. When Form DH is exposed to humidity, it can
absorb water and change to Form HIII at about 30-50% RH or to Form
HI at high humidity around 60-85% RH.
[0173] Form DH was characterized by XRPD. The XRPD was obtained
from Bruker D2 PHASER X-ray Powder Diffractometer (XRPD)
instrument. The general experimental procedures for XRPD are
similar to those for Form HI. The XRPD data are provided in Table
5.
TABLE-US-00005 TABLE 5 XRPD Data of Form DH 2-Theta (.degree.)
Height H % 5.6 57.5 1.0 6.1 69.2 1.2 6.6 62.7 1.1 7.4 2956 50.0 7.5
3560 60.2 9.6 2326 39.4 10.0 534 9.0 10.7 4068 68.8 12.0 128 2.2
12.6 95.4 1.6 13.6 217 3.7 13.9 1487 25.2 14.8 1943 32.9 15.5 780
13.2 16.0 533 9.0 16.1 311 5.3 16.6 450 7.6 17.2 1437 24.3 17.3
1675 28.3 18.1 1061 18.0 18.3 1500 25.4 18.9 282 4.8 19.5 61.7 1.0
20.1 1482 25.1 20.7 1423 24.1 21.6 1585 26.8 22.1 936 15.8 22.9
5909 100 23.4 588 10.0 24.0 955 16.2 24.7 3283 55.6 25.3 94.8 1.6
25.8 754 12.7 26.7 721 12.2 27.1 433 7.3 28.0 335 5.7 28.2 322 5.4
29.5 200 3.4
[0174] Form DH was characterized by DSC. The DSC was obtained from
TA Instruments Differential Scanning calorimetry, Model Q2000 with
autosampler. The DSC instrument conditions similar to those for
Form HI. The DSC thermogram revealed one major endothermal event at
an onset temperature of 93.8.degree. C. with a peak temperature of
97.5.degree. C. which is believed to be the melting of the
compound.
[0175] Form DH was characterized by TGA. The TGA was obtained from
PerkinElmer Thermogravimetric Analyzer, Model Pyris 1. The general
experimental conditions for TGA are similar to those for Form HI. A
weight loss of about 2.3% up to 120.degree. C. was observed and is
believed to be associated mostly with the loss of water.
[0176] Form DH was characterized by DVS. The DVS analysis was
performed on a TA Instruments Vapor Sorption Analyzer, model
VTI-SAt Form DH was generated by pre-drying Form HI on VTI at
40.degree. C. with 0% RH N.sub.2 for 3 h. Then the moisture uptake
profile was completed in one cycle in 5% RH increments with
adsorption from 0% RH to 95% RH followed by desorption in 5%
increments from 95% to 85% RH. The equilibration criteria were
0.0010 wt % in 5 minutes with a maximum equilibration time of 180
minutes. All adsorption and desorption were performed at 25.degree.
C.
[0177] Form DH is hygroscopic and can absorb water stepwise to form
different hydrates. The solid collected after DVS at 85% RH is
characterized as Form HI.
[0178] The present application also relates to a solid dosage form
comprising a pharmaceutical formulation provided herein.
[0179] In some embodiments, the solid dosage form is suitable for
oral administration. In some embodiment, the dosage form provided
herein is in the form of tablets, capsules, pills, powders,
sachets, and soft and hard gelatin capsules. In other embodiments,
the dosage form provided herein is in the form of a capsule.
[0180] In some embodiments, the dosage form provided herein is in
the form of a tablet or capsule. In some embodiments, the dosage
form provided herein is in the form of a tablet.
[0181] In preparing a formulation, Compound 1 di-tosylate salt can
be milled to provide the appropriate particle size prior to
combining with the other ingredients. Compound 1 di-tosylate salt
can be milled to a particle size of less than 200 mesh. The
particle size can be adjusted by milling to provide a substantially
uniform distribution in the formulation, e.g., about 40 mesh.
[0182] Compound 1 di-tosylate salt may be milled using known
milling procedures such as wet milling to obtain a particle size
appropriate for tablet formation and for other formulation types.
Finely divided (nanoparticulate) preparations of the compounds of
the invention can be prepared by processes known in the art, e.g.,
see International App. No. WO 2002/000196.
[0183] The formulations of the invention can include additional
excipients. Examples of suitable additional excipients include
dextrose, sucrose, sorbitol, mannitol, starches, gum acacia,
calcium phosphate, alginates, tragacanth, gelatin, calcium
silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, water, syrup, and methyl cellulose. Other excipients
include: lubricating agents such as talc, magnesium stearate, and
mineral oil; wetting agents; emulsifying and suspending agents;
preserving agents such as methyl- and propylhydroxy-benzoates;
sweetening agents; and flavoring agents. The compositions of the
invention can be formulated so as to provide quick, sustained or
delayed release of the active ingredient after administration to
the patient by employing procedures known in the art.
[0184] The present invention further provides a dosage form which
comprises any of the above-described formulations of the invention.
The term "dosage form" refers to a physically discrete unit
suitable as unitary dosages for human subjects and other mammals,
each unit containing a predetermined quantity of active material
calculated to produce the desired therapeutic effect, in
association with a suitable pharmaceutical excipient. In some
embodiments, the dosage form is a solid dosage form, such as a
tablet or capsule.
[0185] For preparing solid dosage forms such as tablets, Compound 1
di-tosylate salt can be mixed with excipients to form a solid
preformulation composition containing a homogeneous mixture of a
compound of the present invention. When referring to these
preformulation compositions as homogeneous, the active ingredient
is typically dispersed evenly throughout the composition so that
the composition can be readily subdivided into equally effective
unit dosage forms such as tablets, pills and capsules. This solid
preformulation is then subdivided into unit dosage forms of the
type described above containing from, for example, about 0.1 to
about 1000 mg of Compound 1 di-tosylate salt.
[0186] The tablets or pills of provided herein can be coated or
otherwise compounded to provide a dosage form affording the
advantage of prolonged action. For example, the tablet or pill can
comprise an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be separated by an enteric layer which serves to
resist disintegration in the stomach and permit the inner component
to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or
coatings, such materials including a number of polymeric acids and
mixtures of polymeric acids with such materials as shellac, cetyl
alcohol, and cellulose acetate.
[0187] Compound 1 di-tosylate salt may be effective over a wide
dosage range and is generally administered in a pharmaceutically
effective amount. It will be understood, however, that the amount
of the compound actually administered will usually be determined by
a physician, according to the relevant circumstances, including the
condition to be treated, the chosen route of administration, the
actual compound administered, the age, weight, and response of the
individual patient, the severity of the patient's symptoms, and the
like.
[0188] It is appreciated that certain features of the invention,
which are, for clarity, described in the context of separate
embodiments, can also be provided in combination in a single
embodiment (while the embodiments are intended to be combined as if
written in multiply dependent form). Conversely, various features
of the invention which are, for brevity, described in the context
of a single embodiment, can also be provided separately or in any
suitable subcombination.
[0189] As used herein, TsOH refers to p-toluenesulfonic acid,
4-methylbenzenesulfonic acid, or tosylic acid.
[0190] As used herein, and unless otherwise specified, the term
"about," when used in connection with a numeric value or range of
values which is provided to describe a particular salt or solid
form, e.g., a specific temperature or temperature range, such as,
for example, that describing a melting, dehydration, or glass
transition; a mass change, such as, for example, a mass change as a
function of temperature or humidity; a solvent or water content, in
terms of, for example, mass or a percentage; or a peak position,
such as, for example, in analysis by, for example, .sup.13C NMR,
DSC, TGA and XRPD; indicate that the value or range of values may
deviate to an extent deemed reasonable to one of ordinary skill in
the art while still describing the particular solid form.
Specifically, the term "about", when used in this context,
indicates that the numeric value or range of values may vary by 5%,
4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2% or
0.1% of the recited value or range of values while still describing
the particular solid form. The term "about", when used in reference
to a degree 2-theta value refers to +/-0.3 degrees 2-theta or
+/-0.2 degrees 2-theta.
[0191] As used herein, the term "peak" or "characteristic peak"
refers to a reflection having a relative height/intensity of at
least about 3% of the maximum peak height/intensity. As used
herein, the term "crystalline" or "crystalline form" refers to a
crystalline solid form of a chemical compound, including, but not
limited to, a single-component or multiple-component crystal form,
e.g., including solvates, hydrates, clathrates, and
co-crystals.
[0192] The term "crystalline form" is meant to refer to a certain
lattice configuration of a crystalline substance. Different
crystalline forms of the same substance typically have different
crystalline lattices (e.g., unit cells), typically have different
physical properties attributed to their different crystalline
lattices, and in some instances, have different water or solvent
content. The different crystalline lattices can be identified by
solid state characterization methods such as by X-ray powder
diffraction (XRPD). Other characterization methods such as
differential scanning calorimetry (DSC), thermogravimetric analysis
(TGA), dynamic vapor sorption (DVS), and the like further help
identify the crystalline form as well as help determine stability
and solvent/water content.
[0193] Different crystalline forms of a particular substance, such
as Compound 1 di-tosylate salt, can include both anhydrous forms of
that substance and solvated/hydrated forms of that substance, where
each of the anhydrous forms and solvated/hydrated forms are
distinguished from each other by different XRPD patterns, or other
solid state characterization methods, thereby signifying different
crystalline lattices. In some instances, a single crystalline form
(e.g., identified by a unique XRPD pattern) can have variable water
or solvent content, where the lattice remains substantially
unchanged (as does the XRPD pattern) despite the compositional
variation with respect to water and/or solvent.
[0194] An XRPD pattern of reflections (peaks) is typically
considered a fingerprint of a particular crystalline form. It is
well known that the relative intensities of the XRPD peaks can
widely vary depending on, inter alia, the sample preparation
technique, crystal size distribution, filters used, the sample
mounting procedure, and the particular instrument employed. In some
instances, new peaks may be observed or existing peaks may
disappear, depending on the type of the machine or the settings
(for example, whether a Ni filter is used or not). As used herein,
the term "peak" refers to a reflection having a relative
height/intensity of at least about 3% or at least about 4% of the
maximum peak height/intensity. Moreover, instrument variation and
other factors can affect the 2-theta values. Thus, peak
assignments, such as those reported herein, can vary by plus or
minus about 0.2.degree. (2-theta) or about 0.3.degree. (2-theta),
and the term "substantially" as used in the context of XRPD herein
is meant to encompass the above-mentioned variations.
[0195] In the same way, temperature readings in connection with
DSC, TGA, or other thermal experiments can vary about .+-.3.degree.
C. depending on the instrument, particular settings, sample
preparation, etc.
[0196] Crystalline forms of a substance can be obtained by a number
of methods, as known in the art. Such methods include, but are not
limited to, melt recrystallization, melt cooling, solvent
recrystallization, recrystallization in confined spaces such as,
e.g., in nanopores or capillaries, recrystallization on surfaces or
templates such as, e.g., on polymers, recrystallization in the
presence of additives, such as, e.g., co-crystal counter-molecules,
desolvation, dehydration, rapid evaporation, rapid cooling, slow
cooling, vapor diffusion, sublimation, exposure to moisture,
grinding and solvent-drop grinding.
[0197] As used herein, the term "amorphous" or "amorphous form" is
intended to mean that the substance, component, or product in
question is not substantially crystalline as determined, for
instance, by XRPD or where the substance, component, or product in
question, for example is not birefringent when viewed
microscopically. In certain embodiments, a sample comprising an
amorphous form of a substance may be substantially free of other
amorphous forms and/or crystalline forms. For example, an amorphous
substance can be identified by an XRPD spectrum having an absence
of reflections.
[0198] In some embodiments, Compound 1 di-tosylate salt (or
hydrates and solvates thereof) of provided herein are prepared in
batches referred to as batches, samples, or preparations. The
batches, samples, or preparations can include Compound 1
di-tosylate salt in any of the crystalline or non-crystalline forms
described herein, included hydrated and non-hydrated forms, and
mixtures thereof.
[0199] As used herein, the term "crystalline purity," means
percentage of a crystalline form in a preparation or sample which
may contain other forms such as an amorphous form of the same
compound, or at least one other crystalline form of the compound,
or mixtures thereof. As used herein, the term "substantially
crystalline," means a majority of the weight of a sample or
preparation of Compound 1 di-tosylate salt (or hydrate or solvate
thereof) is crystalline and the remainder of the sample is a
non-crystalline form (e.g., amorphous form) of Compound 1
di-tosylate salt. In some embodiments, a substantially crystalline
sample has at least about 95% crystallinity (e.g., about 5% of the
non-crystalline form of Compound 1 di-tosylate salt), preferably at
least about 96% crystallinity (e.g., about 4% of the
non-crystalline form of Compound 1 di-tosylate salt), more
preferably at least about 97% crystallinity (e.g., about 3% of the
non-crystalline form of Compound 1 di-tosylate salt), even more
preferably at least about 98% crystallinity (e.g., about 2% of the
non-crystalline form of Compound 1 di-tosylate salt), still more
preferably at least about 99% crystallinity (e.g., about 1% of the
non-crystalline form of Compound 1 di-tosylate salt), and most
preferably about 100% crystallinity (e.g., about 0% of the
non-crystalline form of Compound 1 di-tosylate salt). In some
embodiments, the term "fully crystalline" means at least about 99%
or about 100% crystallinity.
[0200] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions, and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
immunogenicity or other problem or complication, commensurate with
a reasonable benefit/risk ratio.
[0201] As used herein, the phrase "pharmaceutically acceptable
carrier or excipient" refers to a pharmaceutically-acceptable
material, composition, or vehicle, such as a liquid or solid
filler, diluent, solvent, or encapsulating material. Excipients or
carriers are generally safe, non-toxic and neither biologically nor
otherwise undesirable and include excipients or carriers that are
acceptable for veterinary use as well as human pharmaceutical use.
In one embodiment, each component is "pharmaceutically acceptable"
as defined herein. See, e.g., Remington: The Science and Practice
of Pharmacy, 21st ed.; Lippincott Williams & Wilkins:
Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th
ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American
Pharmaceutical Association: 2009; Handbook of Pharmaceutical
Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company:
2007; Pharmaceutical Preformulation and Formulation, 2nd ed.;
Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009.
[0202] As used herein, the term "contacting" refers to the bringing
together of indicated moieties in an in vitro system or an in vivo
system. For example, "contacting" a LSD1 enzyme with a compound of
the invention includes the administration of a compound of the
present invention to an individual or patient, such as a human,
having a LSD1 enzyme, as well as, for example, introducing a
compound of the invention into a sample containing a cellular or
purified preparation containing the LSD1 enzyme.
[0203] As used herein, the term "individual" or "patient," used
interchangeably, refers to any animal, including mammals,
preferably mice, rats, other rodents, rabbits, dogs, cats, swine,
cattle, sheep, horses, or primates, and most preferably humans.
[0204] As used herein, the phrase "therapeutically effective
amount" refers to the amount of active compound or pharmaceutical
agent that elicits the biological or medicinal response that is
being sought in a tissue, system, animal, individual or human by a
researcher, veterinarian, medical doctor or other clinician. The
therapeutically effective amount will vary depending on the
compound, the disease, disorder or condition and its severity and
the age, weight, etc., of the mammal to be treated. In general,
satisfactory results in subjects are indicated to be obtained at a
daily dosage of from about 0.1 to about 10 g/kg subject body
weight. In some embodiments, a daily dose ranges from about 0.10 to
10.0 mg/kg of body weight, from about 1.0 to 3.0 mg/kg of body
weight, from about 3 to 10 mg/kg of body weight, from about 3 to
150 mg/kg of body weight, from about 3 to 100 mg/kg of body weight,
from about 10 to 100 mg/kg of body weight, from about 10 to 150
mg/kg of body weight, or from about 150 to 1000 mg/kg of body
weight. The dosage can be conveniently administered, e.g., in
divided doses up to four times a day or in sustained-release
form.
[0205] As used herein, the term "treating" or "treatment" refers to
inhibiting the disease; for example, inhibiting a disease,
condition or disorder in an individual who is experiencing or
displaying the pathology or symptomatology of the disease,
condition or disorder (i.e., arresting further development of the
pathology and/or symptomatology) or ameliorating the disease; for
example, ameliorating a disease, condition or disorder in an
individual who is experiencing or displaying the pathology or
symptomatology of the disease, condition or disorder (i.e.,
reversing the pathology and/or symptomatology) such as decreasing
the severity of disease.
[0206] Methods of Use
[0207] The pharmaceutical formulations described herein can inhibit
the activity of LSD1, thus, are useful in treating diseases and
disorders associated with activity of LSD1. The present disclosure
provides methods of treating an LSD1-associated or mediated disease
or disorder in an individual (e.g., patient) by administering to
the individual in need of such treatment a pharmaceutical
formulation provided herein. The present disclosure also provides
pharmaceutical formulation as described herein for use in treating
an LSD1-associated or mediated disease or disorder. Also provided
is the use of a pharmaceutical formulation as described herein in
the manufacture of a medicament for treating an LSD1-associated or
mediated disease or disorder.
[0208] In some embodiments, provided herein is a method of
inhibiting LSD1, wherein said method comprising: contacting an LSD1
with a pharmaceutical formulation provided herein.
[0209] In some embodiments, provided herein is a dosage form (e.g.,
an oral dosage form such as tablets and capsules) comprising a
pharmaceutical formulation provided herein that can inhibit the
activity of LSD1 and thus, useful in treating diseases and
disorders associated with activity of LSD1. The present disclosure
provides methods of treating an LSD1-associated or mediated disease
or disorder in an individual (e.g., patient) by administering to
the individual in need of such treatment a dosage form (e.g., an
oral dosage form such as tablets and capsules) comprising a
pharmaceutical formulation provided herein. The present disclosure
also provides a dosage form (e.g., an oral dosage form such as
tablets and capsules) comprising a pharmaceutical formulation as
described herein for use in treating an LSD1-associated or mediated
disease or disorder. Also provided is the use of a dosage form
(e.g., an oral dosage form such as tablets and capsules) comprising
a pharmaceutical formulation as described herein in the manufacture
of a medicament for treating an LSD1-associated or mediated disease
or disorder.
[0210] In some embodiments, provided herein is a method of
inhibiting LSD1, wherein said method comprising: contacting an LSD1
with a dosage form (e.g., an oral dosage form such as tablets and
capsules) comprising a pharmaceutical formulation provided
herein
[0211] An LSD1-associated or mediated disease refers to any disease
or condition in which LSD1 plays a role, or where the disease or
condition is associated with expression or activity of LSD1. An
LSD1-associated disease can include any disease, disorder or
condition that is directly or indirectly linked to expression or
activity of the LSD1, including over-expression and/or abnormal
activity levels. Abnormal activity levels can be determined by
comparing activity level in normal, healthy tissue or cells with
activity level in diseased cells. An LSD1-associated disease can
also include any disease, disorder or condition that can be
prevented, ameliorated, inhibited or cured by modulating LSD1
activity. In some embodiments, the disease is characterized by the
abnormal activity or expression (e.g., overexpression) of LSD1. In
some embodiments, the disease is characterized by mutant LSD1. An
LSD1 associated disease can also refer to any disease, disorder or
condition wherein modulating the expression or activity of LSD1 is
beneficial. The tosylate salts of the present disclosure can
therefore be used to treat or lessen the severity of diseases and
conditions where LSD1 is known to play a role.
[0212] Diseases and conditions treatable using the tosylate salts
of the present disclosure include, generally cancers, inflammation,
autoimmune diseases, viral induced pathogenesis,
beta-globinopathies, and other diseases linked to LSD1
activity.
[0213] Cancers treatable using tosylate salts according to the
present disclosure include, for example, hematological cancers,
sarcomas, lung cancers, gastrointestinal cancers, genitourinary
tract cancers, liver cancers, bone cancers, nervous system cancers,
gynecological cancers, and skin cancers.
[0214] Exemplary hematological cancers include lymphomas and
leukemias such as acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), acute promyelocytic leukemia (APL),
chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia
(CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma,
non-Hodgkin lymphoma (including relapsed or refractory NHL and
recurrent follicular), Hodgkin lymphoma, myeloproliferative
diseases (e.g., primary myelofibrosis (PMF), polycythemia vera
(PV), essential thrombocytosis (ET)), myelodysplasia syndrome
(MDS), and multiple myeloma.
[0215] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma,
osteosarcoma, rhabdomyosarcoma, angio sarcoma, fibro sarcoma, lipo
sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, harmatoma, and
teratoma.
[0216] Exemplary lung cancers include non-small cell lung cancer
(NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous
cell, undifferentiated small cell, undifferentiated large cell,
adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, chondromatous hamartoma, and mesothelioma.
[0217] Exemplary gastrointestinal cancers include cancers of the
esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma,
lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas
(ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma,
carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma,
carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel (adenocarcinoma, tubular
adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal
cancer.
[0218] Exemplary genitourinary tract cancers include cancers of the
kidney (adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and
urethra (squamous cell carcinoma, transitional cell carcinoma,
adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis
(seminoma, teratoma, embryonal carcinoma, teratocarcinoma,
choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma,
fibroadenoma, adenomatoid tumors, lipoma).
[0219] Exemplary liver cancers include hepatoma (hepatocellular
carcinoma), cholangiocarcinoma, hepatoblastoma, angio sarcoma,
hepatocellular adenoma, and hemangioma.
[0220] Exemplary bone cancers include, for example, osteogenic
sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous
histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma
(reticulum cell sarcoma), multiple myeloma, malignant giant cell
tumor chordoma, osteochronfroma (osteocartilaginous exostoses),
benign chondroma, chondroblastoma, chondromyxofibroma, osteoid
osteoma, and giant cell tumors
[0221] Exemplary nervous system cancers include cancers of the
skull (osteoma, hemangioma, granuloma, xanthoma, osteitis
deformans), meninges (meningioma, meningiosarcoma, gliomatosis),
brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma
(pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma,
retinoblastoma, congenital tumors), and spinal cord (neurofibroma,
meningioma, glioma, sarcoma), as well as neuroblastoma and
Lhermitte-Duclos disease.
[0222] Exemplary gynecological cancers include cancers of the
uterus (endometrial carcinoma), cervix (cervical carcinoma,
pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous
cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified
carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell
tumors, dysgerminoma, malignant teratoma), vulva (squamous cell
carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma,
melanoma), vagina (clear cell carcinoma, squamous cell carcinoma,
botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes
(carcinoma).
[0223] Exemplary skin cancers include melanoma, basal cell
carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles
dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
[0224] The tosylate salts of the present disclosure can further be
used to treat cancer types where LSD1 may be overexpressed
including, for example, breast, prostate, head and neck, laryngeal,
oral, and thyroid cancers (e.g., papillary thyroid carcinoma).
[0225] The tosylate salts of the present disclosure can further be
used to treat genetic disorders such as Cowden syndrome and
Bannayan-Zonana syndrome.
[0226] The tosylate salts of the present disclosure can further be
used to treat viral diseases such as herpes simplex virus (HSV),
varicella zoster virus (VZV), human cytomegalovirus, hepatitis B
virus (HBV), and adenovirus.
[0227] The tosylate salts of the present disclosure can further be
used to treat beta-globinopathies including, for example,
beta-thalassemia and sickle cell anemia.
[0228] In some embodiments, the salts of the present disclosure may
be useful in preventing or reducing the risk of developing the
disease; e.g., preventing or reducing the risk of developing a
disease, condition or disorder in an individual who may be
predisposed to the disease, condition or disorder but does not yet
experience or display the pathology or symptomatology of the
disease.
EXAMPLES
Example 1. Excipient Compatibility
[0229] This study was performed to determine stability of Compound
1 di-tosylate salt, Form I, in combination with various oral solid
dosage form excipients. Observed changes in impurity profile (by
HPLC analysis) suggest chemical incompatibility. The data of the
blends were compared with a control sample (Compound 1 di-tosylate
salt alone) to assess the effect of each excipient relative to
Compound 1 di-tosylate salt alone.
[0230] Blends were prepared by screening the components together;
aliquots were then weighed for stability testing. The binary blend
samples were initially stored under accelerated conditions
(50.degree. C./dry, 50.degree. C./75% RH) in open glass vials and
analyzed by HPLC to determine the potential for drug substance
degradation with each excipient. Based on these results, additional
binary and tertiary mixtures were prepared and stressed at
40.degree. C./dry and 40.degree. C./75% RH. Analysis of a control
(Compound 1 di-tosylate salt alone) was included for comparison at
each condition.
[0231] The following excipients (and their respective functions)
were included in the study: microcrystalline cellulose
(MCC)--diluent, lactose monohydrate--diluent, Prosolve
(MCC/colloidal silica)--diluent, fumaric acid--pH modifier, citric
acid--pH modifier, mannitol-diluent, pregelatinized starch (starch
1500)--diluent/disintegrant/binder, magnesium stearate--lubricant,
sodium stearyl fumarate--lubricant, stearic acid--lubricant,
colloidal silicon dioxide--glidant, polyvinyl pyrrolidone--binder,
croscarmellose sodium--disintegrant, crospovidone--disintegrant,
and sodium starch glycolate--disintegrant.
[0232] Materials are listed in Table 6. Compound 1 di-tosylate salt
was blended at the desired ratio of excipient to drug (see Table 7
below) by weighing each material, mixing with a spatula in a vial,
and screening the mixture 5 times with an 18 mesh screen. A control
sample was included for comparison to the blends. The weight
equivalent of approximately 4 mg of Compound 1 di-tosylate salt was
added to each glass vial and initially set-up at 50.degree. C./dry
(<20% RH) and 50.degree. C./75% RH. Based on results after 1
week at 50.degree. C.; additional samples were set-up at 40.degree.
C./dry and 40.degree. C./75% RH. The additional samples included
tertiary mixtures with Compound 1 di-tosylate salt/lactose/fumaric
acid or citric acid monohydrate. The lactose/fumaric acid
combination was tested at multiple ratios of lactose to fumaric
acid. The 75% RH chamber was maintained by using a saturated sodium
chloride solution in water (inside a closed chamber). The humidity
of the 75% RH chamber was verified with a hygrometer (VWR brand).
Samples were tested by HPLC after 1 week at 50.degree. C. and 1 and
2 weeks at 40.degree. C. (low and high RH at both temperatures).
Data were also measured for samples at 20.degree. C. in closed
vials.
TABLE-US-00006 TABLE 6 Materials Material Supplier/Grade Compend.
Lactose Monohydrate Formost/316 NF Microcrystalline Cellulose
FMC/PH102 NF Starch 1500 Colorcon USP/NF Prosolve JRS-90 USP/NF
Sodium Starch Glycolate JRS USP/NF Croscarmellose Sodium FMC/711 NF
Polyvinyl Pyrrolidone BASF USP Crospovidone ISP/XL NF Colloidal
Silicon Dioxide Cabot/M5P USP/NF Magnesium Stearate Spectrum NF
Sodium Stearyl Fumarate JRS NF Stearic Acid Spectrum NF Citric Acid
Monohydrate Spectrum USP Mannitol Roquette 200SD USP Fumaric Acid
Spectrum NF
TABLE-US-00007 TABLE 7 Weight Ratios Cmpd 1 Cmpd 1 di-tosylate
di-tosylate late salt to salt Excipient Component excipient (g) (g)
mg/vial Cmpd 1 di-tosylate salt alone as 4 control Lactose
Monohydrate 1 to 49 0.20 9.80 200 Microcrystalline Cellulose 1 to
49 0.20 9.80 200 Starch 1500 1 to 49 0.20 9.80 200 Prosolv MCC 1 to
49 0.20 9.80 200 Croscarmellose Sodium 1 to 4 0.20 0.80 20 Sodium
Starch Glycolate 1 to 4 0.20 0.80 20 Polyvinyl Pyrrolidone 1 to 4
0.20 0.80 20 Crospovidone 1 to 4 0.20 0.80 20 Colloidal Silicon
Dioxide 1 to 1 0.30 0.30 8 Magnesium Stearate 1 to 1 0.30 0.30 8
Sodium Stearyl Fumarate 1 to 1 0.30 0.30 8 Stearic Acid 1 to 4 * *
* Mannitol 1 to 49 0.20 9.80 200 Citric Acid Monohydrate 1 to 49
0.20 9.80 200 Fumaric Acid 1 to 49 0.20 9.80 200 Lactose/Fumaric
acid 1:1 1 to 49 0.20 9.80 200 Lactose/Citric acid 1:1 1 to 49 0.20
9.80 200 Lactose/Fumaric Acid 3:1 1 to 49 0.20 9.80 200
Lactose/Fumaric Acid 20:1 1 to 49 0.20 9.80 200 * Cmpd 1
di-tosylate salt/stearic acid added to each vial separately.
[0233] Samples were analyzed by HPLC using the method described
below after dilution in 85% H.sub.2O (0.1% TFA)/15% acetonitrile to
4 mL, sonication for 5 minutes, and filtration (0.45 .mu.m Acrodisc
GHP). One injection per sample was performed at each stability
station. Two methods were performed on the stability samples: a UV
based HPLC method and a mass spectroscopy HPLC method performed for
one impurity (Compound 2). Compound 2 refers to
1-((4-(aminomethyl)-4-(methoxymethyl)piperidin-1-yl)methyl)cyclobutane-1--
carboxylic acid, which has the following structure:
##STR00005##
[0234] Compound 2 is believed to have been formed by cleavage at
the amine-cyclopropyl linkage of Compound 1.
[0235] UV HPLC Method--Instrument: Agilent 1260 HPLC; Column:
Ascentis Express C18 4.6.times.150 mm; Mobile Phase A: Water (0.1%
TFA); Mobile Phase B: Acetonitrile (0.1% TFA); Flow Rate: 1.0
mL/min; Injection volume: 10 .mu.L; UV Detection 214 nm; Column
Temperature:30.degree. C.; Run Time: 33 min; Sample concentration:
1.0 mg/mL as salt; Threshold: 0.1%; Gradient Program:
TABLE-US-00008 Time % A % B 0 98 2 5 85 15 15 60 40 25 5 95 28 5 95
28.3 98 2 33 98 2
[0236] Compound 1 di-tosylate salt degradation (by peak area
percent) is listed in Tables 8, 9, 10 and 11 as a function of
excipient and storage condition. Accelerated storage (50.degree.
C., 40.degree. C.) conditions were used to identify potential
drug-excipient interactions. The drug substance used in this study
had initial total impurity levels of approximately 0.3-0.4% by UV
HPLC method analysis and approximately 0.3% Compound 2. Compound 2
can be determined by a mass spectroscopy HPLC method.
[0237] For all excipient blends, the levels of degradation (based
on the UV HPLC method for impurities other than Compound 2) were
greater than 1% after storage for 1 week at 50.degree. C./dry
(<20% RH). At 50.degree. C./75% RH (Table 8), certain samples
showed higher rates of degradation relative to low RH, while others
were lower. Lactose and the control (Compound 1 di-tosylate salt
alone) appeared to show lower rates at 50.degree. C./75% RH versus
50.degree. C./dry. For lactose, the level of degradation decreased
from 1.4% at 50.degree. C./dry to 0.1% at 50.degree. C./75% RH.
However, for Starch 1500, croscarmellose sodium, sodium starch
glycolate, magnesium stearate and sodium stearyl fumarate samples
at 50.degree. C./75%, impurity levels increased relative to the
50.degree. C./dry samples.
[0238] At 50.degree. C./dry, the levels of Compound 2 were
generally above 2% for both the various excipients blends and the
control (Compound 1 di-tosylate salt alone). For most samples,
Compound 2 levels increased at 75% RH relative to low RH. Based on
the overall levels of degradation observed at 50.degree. C., the
study was expanded to include several additional excipients and the
temperature was decreased to 40.degree. C. The effect of excipient
pH was investigated by including acidic excipients such as fumaric
acid and citric acid. Also, tertiary blends were prepared with
fumaric acid, lactose, and Compound 1 di-tosylate salt to determine
if adding an acidic excipient can decrease the rate of degradation
with lactose.
[0239] The results obtained for samples tested at 40.degree. C./dry
and 40.degree. C./75% RH are listed in tables 10 (UV method) and 11
(% Compound 2 MS Method). These data for the UV HPLC method showed
similar trends to the 50.degree. C. data set where the control and
the lactose blend showed better stability at higher RH versus dry
storage. Many of the other excipients (i.e. Starch 1500,
croscarmellose sodium, sodium starch glycolate, magnesium stearate,
sodium stearyl fumarate. citric acid monohydrate) showed increased
degradation at high RH. The magnesium stearate blend showed very
high reaction rates at 40.degree. C./75% RH by both analytical
methods. The blends with acidic excipients (fumaric acid, citric
acid) showed the lowest levels of degradation at dry RH. In
addition, the tertiary blends with lactose/fumaric acid/and
Compound 1 di-tosylate salt showed lower levels of degradation
versus the blend with only lactose at dry RH. The tertiary blends
also appear to show less effect of humidity at 40.degree. C.
[0240] The results for percent of Compound 2 at 40.degree. C./dry
and 40.degree. C./75% RH indicated that the levels of this impurity
are significant when compared to results obtained from the UV HPLC
method for other impurities. For Compound 1 di-tosylate salt alone,
the levels of Compound 2 observed after 2 w at 40.degree. C./dry
and 2 w 40.degree. C./75% RH were 3.4% and 1.9% respectively. While
the blend with lactose showed higher levels than Compound 1
di-tosylate salt alone, the blends with fumaric acid and citric
acid showed lower levels of Compound 2 at both high and low
humidity. In addition, the tertiary blends with lactose/fumaric
acid/Compound 1 di-tosylate salt showed significantly lower levels
than with pure lactose. The inclusion of fumaric acid appeared to
result in levels of Compound 2 similar to those observed with
Compound 1 di-tosylate salt alone. After 2 weeks at 40.degree.
C./75% RH, the lactose/fumaric acid/Compound 1 di-tosylate salt
tertiary blends showed 1.5-1.9% Compound 2 while Compound 1
di-tosylate salt alone showed 1.9%.
[0241] Based on these observations, the addition of fumaric acid to
a lactose based formulation showed reduced degradation rates;
levels as low as 5% fumaric acid show a significant benefit.
[0242] Data were also obtained after 2 w at 20.degree. C. for both
analytical methods. The levels of degradation are significantly
lower when compared with the 40.degree. C. data. Lactose showed
lower levels of change when compared with other diluents (i.e.
microcrystalline cellulose, starch 1500, Prosolv). As observed at
40.degree. C., magnesium stearate resulted in higher levels of
degradation when compared with other lubricants.
TABLE-US-00009 TABLE 8 Compound 1 di-tosylate salt degradation (UV
Method) as a function of excipient at 50.degree. C./dry, 50.degree.
C./75% RH. Excipient compatibility UV method UV method Component 1
w 50.degree. C. 1 w 50.degree. C./75% RH Cmpd 1 di-tosylate salt
1.4 0.3 alone Lactose Monohydrate 1.3 0.1 Microcrystalline
Cellulose 3.0 2.6 Starch 1500 1.5 6.0 Prosolv MCC 6.3 5.5
Croscarmellose Sodium 1.6 >50% Sodium Starch Glycolate 1.6 3.6
Magnesium Stearate 1.4 >50% Sodium Stearyl Fumarate 1.6 12
TABLE-US-00010 TABLE 9 Compound 1 di-tosylate salt degradation (%
Compound 2) as a function of excipient at 50.degree. C./dry,
50.degree. C./75% RH. Excipient Compatibility % Compound 2 %
Compound 2 Component 1 w 50.degree. C. 1 w 50.degree. C./75% RH
Cmpd 1 di-tosylate salt alone 2.37 2.47 Lactose Monohydrate 2.58
3.45 Microcrystalline Cellulose 8.36 22.06 Starch 1500 2.90 32.12
Prosolv MCC 6.35 20.40 Croscarmellose Sodium 3.29 >50% Sodium
Starch Glycolate 4.81 18.50 Magnesium Stearate 3.32 NA Sodium
Stearyl Fumarate 3.24 43.47
TABLE-US-00011 TABLE 10 Compound 1 di-tosylate salt degradation (UV
Method) as a function of excipient at 40.degree. C./dry, 40.degree.
C./75% RH 1 W 2 W 1 W 2 W 40.degree. C./ 40.degree. C./ 40.degree.
C./ 40.degree. C./ Component dry dry 75% RH 75% RH Cmpd 1
di-tosylate salt alone 0.43 0.86 <0.1 <0.1 Lactose
Monohydrate 0.60 1.1 <0.1 <0.1 Microcrystalline Cellulose 2.5
2.6 0.8 1.0 Starch 1500 0.71 1.1 4.0 6.6 Prosolv MCC 2.76 4.4 1.6
2.4 Croscarmellose Sodium 0.63 1.0 4.8 >>10% Sodium Starch
Glycolate 2.0 3.8 6.7 >>10% Polyvinyl Pyrrolidone 1.8 2.5 1.7
2.1 Crospovidone 1.0 1.3 0.39 1.1 Colloidal Silicon Dioxide 1.2 2.6
1.0 0.60 Magnesium Stearate 0.68 1.1 >>10% >>10% Sodium
Stearyl Fumarate 0.49 0.93 1.1 3.7 Stearic Acid 0.19 0.41 <0.1
<0.1 Mannitol 0.81 0.74 0.63 1.4 Citric Acid Monohydrate <0.1
<0.1 1.2 1.3 Fumaric Acid <0.1 <0.1 0.14 0.30
Lactose/Fumaric acid (50%) <0.1 <0.1 <0.1 <0.1
Lactose/Citric Acid (50%) <0.1 <0.1 0.18 0.91 Lactose/Fumaric
acid (25%) <0.1 0.16 <0.1 <0.1 Lactose/Fumaric acid (5%)
0.37 0.38 <0.1 <0.1
TABLE-US-00012 TABLE 11 Compound 1 di-tosylate salt degradation (%
Compound 2) as a function of excipient at 40.degree. C./dry,
40.degree. C./75% RH. wt % of Compound 2 40.degree. C./ 40.degree.
C./ 40.degree. C. 40.degree. C. 75% RH 75% RH Component 1 W 2 W 1 w
2 w Cmpd 1 di-tosylate salt alone 1.4 3.4 1.3 1.9 Lactose
Monohydrate 3.1 5.6 1.4 3.3 Microcrystalline Cellulose 5.9 8.9 6.8
10.1 Starch 1500 3.1 3.6 11.3 27.6 Prosolv MCC 5.3 8.2 8.0 14.5
Croscarmellose Sodium 2.9 5.0 32.2 >50% Sodium Starch Glycolate
6.7 9.9 34.7 >50% Polyvinyl Pyrrolidone 4.4 6.8 4.6 7.1
Crospovidone 2.3 3.5 2.8 7.9 Colloidal Silicon Dioxide 1.7 3.9 0.6
1.1 Magnesium Stearate 4.0 5.2 >50% >50% Sodium Stearyl
Fumarate 1.8 3.2 7.5 14.4 Stearic Acid 1.2 2.2 1.7 3.0 Mannitol 1.3
3.4 1.1 2.0 Citric Acid Monohydrate 0.38 0.78 0.52 0.65 Fumaric
Acid 0.67 0.89 0.73 0.92 Lactose: Fumaric Acid (50% 0.77 0.85 1.2
1.5 FA) Lactose: Citric Acid 1:1 (50% 1.3 1.9 2.0 2.0 CA) Lactose:
Fumaric Acid (25% 1.2 1.6 1.3 1.5 FA) Lactose: Fumaric Acid (5% 2.2
3.5 1.4 1.9 FA)
TABLE-US-00013 TABLE 12 Compound 1 di-tosylate salt compatibility
at 20.degree. C. 2 W 20.degree. C. % Component 20.degree. C. 2 w UV
method of cmpd 2 Cmpd 1 di-tosylate salt alone <0.1 0.43 Lactose
Monohydrate <0.1 0.63 MCC 0.43 1.1 Starch 1500 0.52 0.86 Prosolv
MCC 1.0 2.2 Croscarmellose Sodium 0.37 1.0 Sodium Starch Glycolate
1.5 4.7 Polyvinyl Pyrrolidone 0.62 1.5 Crospovidone 0.38 1.1
Colloidal Silicon Dioxide <0.1 0.55 Magnesium Stearate 0.67 1.9
Sodium Stearyl Fumarate <0.1 0.82 Stearic Acid <0.1 0.53
Mannitol 0.54 0.60 Citric Acid Monohydrate <0.1 0.48 Fumaric
Acid <0.1 0.43
[0243] Compound 1 di-tosylate salt shows changes in impurity
profile after storage at 40.degree. C. (low and high RH) for both
as Compound 1 di-tosylate salt alone and blends with common
excipients, showing degradation with a broad range of excipients.
Although Compound 1 di-tosylate salt alone was observed to be
relatively stable at 40.degree. C./75% (2 w) by the UV HPLC method,
increased levels of Compound 2 were detected by the MS HPLC
method.
[0244] At 40.degree. C./75% RH, the primary degradation is related
to formation of Compound 2. In addition, at 40.degree. C./75% RH,
Compound 1 di-tosylate salt alone is more stable than at 40.degree.
C./dry; this observation also held for Compound 1 di-tosylate salt
blended with lactose monohydrate. The blend with lactose showed
lower levels of change when compared with the other common diluents
such as microcrystalline cellulose and starch 1500. At 40.degree.
C., the levels of impurities were lower in the presence of selected
excipients, specifically fumaric acid. Tertiary mixtures with
lactose/fumaric acid/Compound 1 di-tosylate salt were more stable
than the binary blends with only lactose.
Example 2. Stability Study
[0245] The following study was performed to determine the chemical
stability of 1 mg tablets of Compound 1 di-tosylate, Form I, at
various conditions of temperature and humidity. A direct
compression process was used to prepare blends, which were then
compressed at 1 mg dosage strength. The blends were composed of
Compound 1 di-tosylate salt (API), lactose monohydrate (Fast Flo),
with/without fumaric acid, and sodium stearyl fumarate. The tablets
of the current study were packaged in HDPE bottles (induction
sealed) and stored at 5.degree. C., 25.degree. C./60% RH, and
40.degree. C./75% RH; analysis was performed by two HPLC methods
(for UV detectable impurities and % Compound 2 with the MS based
HPLC method). Tablet formulas are listed in Table 13 as % and
mg/tablet.
TABLE-US-00014 TABLE 13 Composition for 1 mg Tablet Lots 1 and 2
(2.0 mg Compound 1 as salt is equivalent to 1.0 mg as free base) %
composition mg/tablet Lot 1 Lot 2 Lot 1 Lot 2 Compound 1
di-tosylate salt 2.54 2.54 2.0 2.0 Lactose Monohydrate Fast Flo NF
95.5 85.5 76.4 68.4 Fumaric Acid NF 0.0 10.0 0.0 8.0 Sodium Stearyl
Fumarate NF 2.0 2.0 1.6 1.6 100.0 100.0 80.0 80.0
[0246] Two lots of tablets were prepared. The procedures for
preparing the 1 mg tablets are as follows:
TABLE-US-00015 steps Lot 1 Lot 2 1 Screen API-60 mesh and weigh the
API Screen API-60 mesh and weigh API 2 Screen lactose 45 mesh and
weigh lactose Process fumaric acid with Comill and weigh portion 1
(10% of formulation) fumaric acid 3 Blend API with lactose manually
and Screen lactose 45 mesh and weigh portion 1 screen 60 mesh (10%
of formulation) 4 Weigh screened lactose portion 2 (30% of Blend
API with lactose manually and screen formulation) 60 mesh 5 Blend
the mixture from steps 1-4 for 5 min Weigh screened lactose portion
2 (30% of and screen 60 mesh formulation) 6 Weigh screened lactose
portion 3 (55.5% Blend the lactose of step 5 with the of
formulation) and add to the mixture of API/lactose mixture of step
4 for 5 min and step 5 screen 60 mesh 7 Blend the mixture of step 6
for 5 minutes Weigh screened lactose portion 3 (45.5% of
formulation) and add to the mixture of step 6 8 Screen sodium
stearyl fumarate and weigh Add fumaric acid to the mixture of step
7 and sodium stearyl fumarate blend for 5 minutes 9 Blend sodium
stearyl fumarate of step 8 Screen sodium stearyl fumarate and weigh
with API/lactose mixture for 3 minutes 10 Compress the mixture of
step 9 with a Blend sodium stearyl fumarate of step 9 7/32 inch
round tooling (80 mg target wt, with API/lactose/fumaric acid 3
minutes 5kp) 11 Compress the mixture of step 10 with a 7/32 inch
round tooling (80 mg target wt, 5kp) API = Compound 1 di-tosylate
salt
[0247] Blending was performed using a Turbula Blender and tablet
compression was performed using a Globe Pharma Minipress with 7/32
inch round tooling. Excipient information is listed below:
TABLE-US-00016 Material Supplier/Grad Compen Lactose Monohydrate
Formost/316 NF Fumaric Acid Spectrum NF Sodium Stearyl Fumarate JRS
NF Compound 1 di-tosylate salt INCYTE NA
[0248] The milling process for the fumaric acid for Lot 2 was
performed with a Quadro Comill. The material was passed through
screens 032R and 018R at 2500 RPM (one pass each screen size).
[0249] The dissolution data was obtained using USP Apparatus II: 50
RPM, water pH 2 as media, 500 mL volume, and at 37.degree. C. The
dissolution data of Lot 2 (with fumaric acid) is provide in the
table below.
TABLE-US-00017 TABLE 14 Dissolution of Tablets with Fumaric Acid
Time % dissolved 5 min 68 15 min 91 30 min 98 45 min 99
[0250] Tablets were packaged (25 tablets/bottle) in 40 cc HDPE
bottles and induction sealed. The bottles were stored at 5.degree.
C., 25.degree. C./60% RH and 40.degree. C./75% RH.
[0251] Tablets were analyzed by HPLC using the method described
below after dilution in 85% H.sub.2O (0.1% TFA)/15% acetonitrile (4
tablets in 20 mL), sonication for 10 minutes, and filtration (0.45
.mu.m Acrodisc GHP). Two injections per sample were performed at
each stability station. Two methods were performed on the stability
samples: a UV based HPLC method (for assay, related substances) and
a mass spectroscopy HPLC method performed for one impurity
(Compound 2). Standards were prepared with API at the same
theoretical concentration as the UV based HPLC method for assay
determination.
[0252] UV HPLC Method--Instrument: Agilent 1260 HPLC Column:
Ascentis Express C18 4.6.times.150 mm; Mobile Phase A: Water (0.1%
TFA); Mobile Phase B: Acetonitrile (0.1% TFA); Flow Rate: 1.0
mL/min; Injection volume: 25 .mu.L; UV Detection: 214 nm; Column
Temperature: 30.degree. C.; Run Time: 33 min; Threshold: 0.1%;
Gradient Program:
TABLE-US-00018 Time % A % B 0 98 2 5 85 15 15 60 40 25 5 95 28 5 95
28.3 98 2 33 98 2
[0253] The 1 mg tablet stability (Table 15) is listed as a function
of storage condition after 2 weeks. The drug substance batch used
in this study had initial total impurity levels of approximately
0.3-0.4% by UV HPLC method analysis and approximately 0.3% Compound
2. Example 1 excipient compatibility studies for powder blends
showed a significant protective effect of adding fumaric acid, both
in binary mixtures with API and in tertiary mixtures with
API/lactose monohydrate.
[0254] The stability of the 1 mg tablets showed a strong effect of
storage temperature and the impact of fumaric acid. Lot 1 did not
contain fumaric acid while Lot 2 contained 10% fumaric acid. After
2 weeks at 40.degree. C./75% RH, the assay values were 42.9% and
77.5% for Lots 1 and 2 respectively. The percent of Compound 2
increased to over 50% for the Lot 1 (without fumaric acid), while
Lot 2 showed 20% Compound 2 indicating the protective effect of
fumaric acid. The UV detectable impurities showed a similar trend,
with Lot 2 showing improved stability.
[0255] After 2 weeks at 25.degree. C./60% RH, improved stability
was also observed for Lot 2. The levels of Compound 2 for Lot 1
(without fumaric acid) were significantly greater (4.6%) when
compared with Lot 2 (1.8%).
[0256] At 5.degree. C. (2 weeks) both formulations appeared to be
relatively stable with respect to chemical degradation in terms of
assay, UV detectable impurities, and percent of Compound 2.
TABLE-US-00019 TABLE 15 1 mg Tablet Stability in HDPE Bottles Assay
Impurities: Compound 2 (% label) UV (%) Lot 1 Lot 2 Lot 1 Lot 2 Lot
1 Lot 2 Initial 98.2 96.9 0.34 0.33 0.46 0.29 5.degree. C. 98.4
96.3 0.36 0.32 0.38 0.36 25.degree. C./60% RH 90.9 95.8 0.92 0.64
4.6 1.8 40.degree. C./75% RH 42.9 77.5 25 5.5 >50% 20 Lot 1
(without Fumaric Acid), Lot 2 (with 10% Fumaric Acid)
[0257] Compound 1 di-tosylate salt tablets (1 mg free base dosage
strength) were compressed from lactose monohydrate based
formulations with and without fumaric acid. Example 1 excipient
compatibility studies had shown that API blends containing lactose
and fumaric acid were more stable than blends with only lactose.
Two tablet formulations were compressed with the compositions
listed in Table 13 and packaged in 40 cc HDPE bottles. Both
formulations contained lactose monohydrate as a diluent and sodium
stearyl fumarate as a lubricant. Lot 2, which contained 10% fumaric
acid, showed significantly lower rates of degradation after 2 weeks
at both 25.degree. C./60% RH and 40.degree. C./75% RH indicating an
advantage of having fumaric acid in the formulation.
Example 3. Tablet Prepared with Form HI of Compound 1 Di-Tosylate
Salt
[0258] Tablets of Form HI of Compound 1 di-tosylate salt were
prepared with the following compositions.
TABLE-US-00020 TABLE 16 Composition for 1 mg Tablet % comp.
mg/tablet Compound 1 di-tosylate salt 2.58 2.0 Lactose Monohydrate
Fast Flo 85.46 68.4 NF Fumaric Acid NF 10.0 8.0 Sodium Stearyl
Fumarate NF 2.0 1.6 100.0 80.0 (2.0 mg Compound 1 as salt is
equivalent to 1.0 mg as free base)
[0259] The procedures to prepare the tablets are as follows.
TABLE-US-00021 Steps 1 Screen API-80 mesh and weigh 2 Process
fumaric acid with Comill and weigh. 3 Mix lactose portion 1 (10% of
formulation) with API and fumaric acid. Screen 60 mesh and blend
the mixture for 5 mins 4 Weigh screened lactose portion 2 (30% of
formulation) and blend with the mixture of step 3 for 5 mills and
screen 60 mesh 5 Weigh screened lactose portion 3 (45.5% of
formulation) and add to the mixture of step 4. Blend the resulting
mixture for 5 mins 6 Screen sodium stearyl fumarate and weigh 7
Blend the screened sodium stearyl fumarate with API/lactose/
fumaric acid mixture of step 5 for 3 minutes 8 Compress the mixture
of step 7 with a 7/32 inch round tooling (80 mg target wt, 5kp)
[0260] A study of the stability of the tablet was carried out using
similar procedures as in Example 2 and the results are as
follows.
TABLE-US-00022 TABLE 17 Tablet Stability 1 month at 5.degree. C.,
25.degree. C./60% RH Condition: 25.degree. C./ 40.degree. C./
5.degree. C. 60% RH 75% RH Test Initial 1 m 3 m 1 m 3 m 1 m Assay
100.1 100.6 101.8 98.9 95.7 90.7 UV Impurities <0.05 <0.05
<0.05 <0.05 0.08 0.39 (%) Compound 2 0.07 0.10 0.19 0.59 0.65
1.5 (%)
Example 4. Wet Granulation Process Using Form HI of Compound 1
Di-Tosylate Salt
[0261] Tablets described herein can also be prepared according to
the wet granulation process below. The wet granulation was
performed in a high shear granulator with an impeller blade and
chopper blade rotating as water is added. The amount of water was
controlled to prevent overwetting. The wet granules can be dried in
a static oven or fluid bed dryer. The process was performed to
create a well distributed mixture of lactose monohydrate and
fumaric acid. Table 19 below shows the tablet compositions prepared
using the wet granulation process. Stability data for formulation A
prepared according to the process below (wet granulation process)
and a composition similar to that of the tablet in Table 16 are
listed in Table 18. Reduced levels of Compound 2 were observed
after 1 month of storage for a tablet prepared using the wet
granulation process. Stability data for formulation B prepared
according to the process below is shown in Table 20.
TABLE-US-00023 Steps 1 Screen API-60 or 80 mesh and weigh 2 Screen
fumaric acid and lactose (40 mesh), and weigh 3 Blend fumaric acid
with lactose for 10 min 4 Wet granulate fumaric acid and lactose
and dry 5 Process dried wet granulation of step 4 with Comill and
screen (40 mesh). Blend wet-granulated lactose/fumaric acid mixture
with API (in 2 steps). Screen lubricant (sodium stearyl fumarate or
stearic acid) and add lubricant to the mixture of
API/lactose/fumaric acid 6 Blend lubricant with API/lactose/fumaric
acid for 3 minutes 7 If necessary, add glidant (colloidal silica)
to the mixture of step 6 8 Compress the mixture of step 6 or step 7
with a 7/32 inch round tooling (80 mg target) API = Compound 1
di-tosylate salt
TABLE-US-00024 TABLE 18 Tablet Stability 1 month at 5.degree. C.,
25.degree. C./60% RH, 40.degree. C./75% RH for Formulation A Wet
Granulation Dry Blend Compound 2 (%) Compound 2 (%) Initial 0.06
0.07 5.degree. C. 0.06 0.10 25.degree. C./60% RH 0.25 0.59
40.degree. C./75% RH 0.82 1.5
TABLE-US-00025 TABLE 19 Tablets Composition % comp. mg/tablet
Formulation A Compound 1 di-tosylate salt, Form HI 2.5 2.0 Lactose
Monohydrate Fast Flo NF 85.5 68.4 Fumaric Acid NF 10.0 8.0 Sodium
Stearyl Fumarate NF 2.0 1.6 100.0 80.0 Formulation B Compound 1
di-tosylate salt, Form HI 2.5 2.0 Lactose Monohydrate Fast Flo NF
85.5 68.4 Fumaric Acid NF 10.0 8.0 Stearic Acid NF 1.5 1.2
Colloidal Silica NF 0.5 0.4 100.0 80
TABLE-US-00026 TABLE 20 Tablet Stability at 5.degree. C.,
25.degree. C./60% RH, 40.degree. C./75% RH for Formulation B %
Compound 2 Condition 1 m 3 m 6 m 5.degree. C. 0.10 0.15 0.16
25.degree. C./60% RH 0.26 0.54 0.57 30.degree. C./65% RH 0.32 0.55
0.52 40.degree. C./75% RH 0.65 1.1 1.5 Initial: 0.12%
Example 5. Capsule Formulation Prepared with Form HI of Compound 1
Di-Tosylate Salt
[0262] A capsule formulation was prepared with the composition
listed in Table 21 according to the process steps below and the wet
granulation process described in Example 4. The stability was
determined after storage for 3 months in 40 cc HDPE bottles at
25.degree. C./60% RH and 40.degree. C./75% RH. The stability
results in Table 22 show reduced levels of compound 2.
TABLE-US-00027 Steps 1 Screen API-60 or 80 mesh and weigh 2 Screen
fumaric acid and lactose (40 mesh), and weigh 3 Blend fumaric acid
with lactose for 10 min 4 Wet granulate fumaric acid and lactose
and dry 5 Process dried wet granulation of step 4 with Comill and
screen (40 mesh). Blend wet-granulated lactose/fumaric acid mixture
with API (in 2 steps). 6 Screen lubricant (stearic acid) and
glidant (colloidal silicon dioxide), weigh-add to the mixture of
API/lactose/fumaric acid 7 Blend with API/lactose/fumaric acid for
3 minutes. Discharge from blender 8 Fill into size 3 capsules
TABLE-US-00028 TABLE 21 Compound 1 Capsule Formulation: 1 mg %
comp. mg/capsule Compound 1 di-tosylate salt, Form HI 2.5 2.0
Lactose Monohydrate Fast Flo NF 85.5 68.4 Fumaric Acid NF 10.0 8.0
Stearic Acid NF 1.5 1.2 Colloidal Silica NF 0.5 0.4 100.0 80
TABLE-US-00029 TABLE 22 Capsule Stability 3 month at 25.degree.
C./60% RH, 40.degree. C./75% RH 1 mg Capsule Stability Condition %
Compound 2 25.degree. C./60% RH 0.43 40.degree. C./75% RH 0.88
Example 6
Synthesis of
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate) (12) (Compound 1 di-tosylate
salt)
##STR00006## ##STR00007## ##STR00008##
[0263] Step 1. Synthesis of 1-tert-butyl
4-(methoxymethyl)piperidine-1,4-dicarboxylate (2)
##STR00009##
[0265] To a solution of N,N-diisopropylamine (165.0 mL, 1180 mmol)
in THF was added 2.5 M n-butyllithium in hexane (0.46 L, 1150 mmol)
at -78.degree. C. The reaction mixture was stirred at -78.degree.
C. for 15 minutes, and warmed to 0.degree. C. for 20 minutes.
[0266] The above prepared LDA solution was added to a flask
containing 1-t-butyl 4-methyl piperidine-1,4-dicarboxylate (200.0
g, 822.03 mmol) in THF (2.4 L) at -78.degree. C. The reaction
mixture was stirred at -78.degree. C. for 10 minutes, then warmed
to -40.degree. C. over 1 hour. The reaction mixture was re-cooled
to -78.degree. C., then chloromethyl methyl ether (93.6 mL, 1230
mmol) was added dropwise. The mixture was stirred for 2.5 hours
allowing the reaction to come to room temperature. The reaction
mixture was quenched with saturated aqueous NaHCO.sub.3, and
extracted with ethyl acetate (2.times.1.5 L). The combined organics
were washed with water and brine, dried over MgSO.sub.4, filtered
and concentrated to give an oil product (2). The residue was used
in the next step without further purification (quantitative yield).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 3.85 (d, J=13.9 Hz, 2H),
3.74 (s, 3H), 3.39 (s, 2H), 3.31 (s, 3H), 3.02-2.90 (m, 2H),
2.13-2.03 (m, 2H), 1.40-1.46 (m, 11H).
Step 2. Synthesis of tert-butyl
4-(hydroxymethyl)-4-(methoxymethyl)piperidine-1-carboxylate (3)
##STR00010##
[0268] To a dried 22 L 5-neck round bottom flask equipped with stir
shaft for mechanical stirring, thermocouple, N.sub.2 inlet,
addition tube and yellow cap for pressure release was charged 3225
mL dry THF. The solution was cooled to -15.degree. C. using dry
ice/IPA bath and charged 1.0 M lithium tetrahydroaluminate in THF
(1180 mL, 1180 mmol) to the reactor via cannula directly from
vender bottles (the additional LAH was used for EtOAc that is
present in the substrate by NMR). The mixture was allowed to warm
to -5.degree. C. A solution of 1-tert-butyl
4-(methoxymethyl)piperidine-1,4-dicarboxylate (429.50 g, 1494.7
mmol) in THF (4000 mL) was prepared and transferred to a 12 L round
bottom flask. The ester was slowly added to the LAH solution using
positive N.sub.2 pressure to deliver solution via addition tube
(like a plastic cannula). The internal temperature was kept below
8.degree. C. during addition by adjusting the rate of addition. The
reaction mixture was stirred at 0.degree. C. for 1 hour.
[0269] The reaction mixture was quenched using aq. 1.0N NaOH (260
mL). The initial 21 mL was added slowly under N.sub.2. Vigorous
H.sub.2 evolution and a temperature increase were observed during
this part of the quench. Temperature was not allowed to increase
above 8.degree. C. Solids began to form and aqueous addition could
be performed more rapidly without noticeable gas evolution and
temperature increase. Total quenching time was 20 minutes. The
mixture was allowed to stir for 15 minutes to break up solids.
Celite (500 g) was added and stirred for 45 minutes. The mixture
was filtered. The filter cake was washed with ethyl acetate (EtOAc)
(2000 mL). The filtrate was added to separation funnel and
partitioned between EtOAc (6000 mL) and water (1000 mL). Layers
were slow to separate. Some emulsion was observed. The material was
purified by Biotage (0-30% EtOAc in hexane) to get pure product (3)
(369.5 g, 95.3%). 41 NMR (400 MHz, CDCl.sub.3) .delta. 3.62 (s,
2H), 3.45 (d, J=2.3 Hz, 1H), 3.41-3.32 (m, 7H), 2.33 (s, 2H),
1.55-1.42 (m, 13H).
Step 3. Synthesis of [4-(methoxymethyl)piperidin-yl]methanol
hydrochloride (4)
##STR00011##
[0271] To a solution of tert-butyl
4-(hydroxymethyl)-4-(methoxymethyl)piperidine-1-carboxylate (113.70
g, 438.42 mmol) in DCM (0.667 L) was added 4.0 M HCl in dioxane
(0.767 mL, 3070 mmol) at 0.degree. C. The reaction mixture was
stirred at room temperature for 1 hour. Filtration of the reaction
mixture provided pure product (4) (77.0 g, 89.8%). LC-MS calculated
for C.sub.24H.sub.18ClNO.sub.2 [M+H].sup.+ m/z: 196.1; found 196.1.
.sup.1H NMR (400 MHz, DMSO) .delta. 9.02 (s, 1H), 3.31-3.18 (m,
7H), 2.98 (d, J=6.0 Hz, 4H), 1.61-1.53 (m, 4H).
Step 4. Synthesis of dibenzyl cyclobutane-1,1-dicarboxylate(5b)
##STR00012##
[0273] To a solution of 1,1-cyclobutanedicarboxylic acid (50.00 g,
346.9 mmol) in DMF (180 mL) was added trimethylamine (102 mL, 728
mmol) at 0.degree. C. (keeping temperature below 15.degree. C.
during the addition). The reaction mixture was stirred at 0.degree.
C. for 15 minutes, then benzyl bromide (144 mL, 1210 mmol) was
added (keeping temperature below 30.degree. C.). After 10 minutes,
the ice bath was removed. The reaction mixture was stirred at room
temperature overnight.
[0274] To the reaction mixture was added water (300 mL). The
mixture was partitioned between DCM (300 mL) and aqueous solution.
The organics were washed with 1.0 N HCl solution (200 mL), 10%
NaHCO.sub.3 solution (200 mL) and brine (200 mL), then dried over
MgSO.sub.4 and concentrated to give crude material (5b) (111.10 g),
which was used for next step. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.37-7.24 (m, 10H), 5.17 (s, 4H), 2.64-2.55 (t, J=8.0 Hz,
4H), 2.02 (p, J=8.0 Hz, 2H).
Step 5. Synthesis of benzyl 1-formylcyclobutanecarboxylate (5)
##STR00013##
[0276] To a solution of dibenzyl cyclobutane-1,1-dicarboxylate
(30.00 g, 92.49 mmol) in DCM (200.00 mL) at -75.degree. C. was
added 1.0 M diisobutylaluminum hydride in DCM (185 mL) dropwise.
The temperature was controlled between -70.degree. C. and
-60.degree. C. The reaction mixture was stirred at -75.degree. C.
for 1 hour.
[0277] The reaction was quenched with slow addition of 1.0 M
hydrogen chloride in water (200.0 mL). The resulting mixture was
warmed to room temperature and stirred for another 30 minutes. The
mixture was partitioned between DCM and aqueous solution. The
organic layer was washed with water and brine, dried over
MgSO.sub.4 and concentrated to give crude product. Biotage (0-10%
EtOAc in hexane) gave pure product (5) 11.6 g. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 9.82 (s, 1H), 7.37 (p, J=4.3 Hz, 5H), 5.25
(s, 2H), 2.51 (t, J=8.0 Hz, 4H), 2.11-1.89 (p, J=8.0 Hz, 2H).
Step 6. Synthesis of benzyl
1-((4-(hydroxymethyl)-4-(methoxymethyl)piperidin-1-yl)methyl)cyclobutane--
1-carboxylate (6)
##STR00014##
[0279] To a solution of [4-(methoxymethyl)piperidin-4-yl]methanol
hydrochloride (10.8 g, 55.4 mmol) and benzyl
1-formylcyclobutanecarboxylate (14.40 g, 52.78 mmol) in DCM (300
mL) was added trimethylamine (18.4 mL, 132 mmol) at room
temperature. The reaction mixture was stirred at room temperature
for 1 hour. Sodium triacetoxyborohydride (22.4 g, 106 mmol) was
added with a water bath portionwise. The reaction mixture was
stirred at room temperature overnight.
[0280] To the reaction mixture was added saturated NaHCO.sub.3
solution (200 mL). The mixture was partitioned between DCM and
NaHCO.sub.3 solution. The organics were dried and concentrated to
provide oil crude product. Biotage (EtOAc/hexane: 0-45%) gave pure
product (6) (16.6 g, 87%). LC-MS calculated for
C.sub.21H.sub.31NO.sub.4 [M+H].sup.+ m/z: 362.2; found 362.2.
.sup.1H NMR (400 MHz, CD.sub.3CN) .delta. 7.47-7.30 (m, 5H), 5.16
(s, 2H), 3.38 (s, 2H), 3.30 (s, 3H), 3.24 (s, 2H), 2.71 (s, 2H),
2.43 (ddd, J=12.1, 9.4, 7.2 Hz, 2H), 2.36-2.28 (m, 4H), 2.09-1.82
(m, 4H), 1.39-1.31 (m, 4H).
Step 7. Synthesis of Benzyl
1-{[4-formyl-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylat-
e (7)
##STR00015##
[0282] To a solution of oxalyl chloride (226 mL, 339 g, 2.67 moles)
in dichloromethane (1.1 L) was added a solution of dimethyl
sulfoxide (378 mL, 416 g, 5.32 moles) in dichloromethane (500 mL)
over one hour, while maintaining the internal temperature at below
-55.degree. C. After stirring at -50.degree. C. for 30 minutes, a
solution of benzyl
1-((4-(hydroxymethyl)-4-(methoxymethyl)piperidin-1-yl)methyl)cyclobutane--
1-carboxylate (475 g, 1.315 mol) in dichloromethane (1.1 L) was
added over 45 minutes, maintaining the internal temperature below
-50.degree. C. After stirring at -50.degree. C. for 30 minutes,
triethylamine (1480 mL, 10.62 moles) was added. The reaction
temperature rose to 15.degree. C. during the addition. After
stirring for 20 minutes, ice cold water (5 L) was added and the
layers were separated. The organic layer was washed with water (2
L) and 10% sodium bicarbonate (6.2 L). Each aqueous layer was
re-extracted with dichloromethane (3.5 L). The combined organic
layers were concentrated under reduced pressure. The crude product
was purified over silica gel (5 kg), eluting with a gradient 0 to
100% ethyl acetate in heptane to give compound (7) (402 g, 85%
yield, 98% purity) as colorless oil. LC-MS calculated for
C.sub.21H.sub.29NO.sub.4 [M+H].sup.+ m/z: 361.2; found 361.2.
.sup.1H NMR (400 MHz, CD.sub.3CN) .delta. 9.47 (s, 1H), 7.47-7.33
(m, 5H), 5.16 (s, 2H), 3.38 (s, 2H), 3.26 (s, 3H), 2.67 (s, 2H),
2.54-2.38 (m, 4H), 2.16-1.93 (m, 4H), 1.91-1.78 (m, 4H), 1.38 (ddd,
J=13.9, 10.3, 4.0 Hz, 2H).
Step 8. Synthesis of benzyl
1-((4-(methoxymethyl)-4-(((1R,2S)-2-phenylcyclopropylamino)methyl)piperid-
in-1-yl)methyl)cyclobutanecarboxylate (9) and Benzyl
1-{[4-({(tert-butoxycarbonyl)
[(1R,2S)-2-phenylcyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-1-y-
l]methyl}cyclobutanecarboxylate (10)
##STR00016##
[0284] Benzyl
1-{[4-formyl-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylat-
e (7) (136.10 g, 378.62 mmol) and (1R,2S)-2-phenylcyclopropanamine
(8) (61.0 g, 458.0 mmol) were mixed in methylene chloride (1225
mL). The mixture was then concentrated under vacuum with a bath
temperature of 40.degree. C. The oily residue was re-dissolved in
methylene chloride (1225 mL). The solution was then concentrated
under vacuum with a bath temperature of 40.degree. C. The formation
of imine was confirmed by LC-MS at pH 10.
[0285] The residue was dissolved in methylene chloride (1225 mL),
acetic acid (45.1 mL, 793.0 mmol) was added, followed by sodium
triacetoxyborohydride (79.4 g, 793.0 mmol). The mixture was stirred
for 1.5 hours. HPLC indicated the completion of the reaction.
Methylene chloride (1225 mL) was added to dilute the reaction. To
the mixture was added 7% aqueous sodium bicarbonate (2449.6 g), the
mixture was stirred for 30 minutes and DCM phase was collected. The
organic phase was washed with aqueous 7% sodium bicarbonate (2449.6
g), then concentrated under vacuum to about 1300-1500 mL volume,
and used directly for the next step.
[0286] To the above solution was added di-tert-butyldicarbonate
(180.0 g, 377.63 mmol). The mixture was stirred at room temperature
overnight. To the reaction mixture was added aqueous 7% sodium
bicarbonate and after stirring for 30 minutes, the organic phase
was collected, dried over MgSO.sub.4 and concentrated. The residue
was purified by Biotage (0-20% ethyl acetate in hexane, checked by
anisaldehyde as stain) to give compound (10) (190.0 g, 87.2%).
Compound (9): LC-MS calculated for C.sub.30H.sub.4ON.sub.2O.sub.3
[M+H].sup.+ m/z: 477.3; found 477.3. .sup.1H NMR (400 MHz,
D.sub.2O) .delta. 7.49-7.23 (m, 8H), 7.18 (d, J=7.3 Hz, 2H), 5.23
(s, 2H), 3.56 (s, 2H), 3.34 (s, 3H), 3.23 (s, 2H), 3.16 (s, 3H),
3.01 (s, 2H), 2.48 (dt, J=11.2, 8.1 Hz, 3H), 2.17-1.93 (m, 4H),
1.55-1.49 (m, 5H), 1.37 (q, J=7.2 Hz, 1H). Compound (10): LC-MS
calculated for C.sub.35H.sub.48N.sub.2O.sub.5 [M+H].sup.+ m/z:
577.3; found 577.3. .sup.1H NMR (400 MHz, CD.sub.3CN) .delta.
7.46-7.23 (m, 8H), 7.15 (dd, J=28.9, 7.3 Hz, 2H), 5.15 (s, 2H),
3.44 (d, J=14.5 Hz, 1H), 3.31-3.07 (m, 5H), 2.78-2.67 (m, 3H), 2.43
(dd, J=11.1, 5.8 Hz, 4H), 2.26 (ddd, J=24.0, 11.7, 4.7 Hz, 4H),
2.08-1.95 (m, 4H), 1.86 (p, J=7.3, 6.6 Hz, 2H), 1.55-1.44 (m, 1H),
1.44-1.28 (m, 13H), 1.21 (dq, J=13.5, 6.8 Hz, 1H).
[0287] Compound (10) can also be purified by reacting compound (10)
with L-tartaric acid in the presence of isopropanol, methanol, and
n-heptane to form compound (10) L-tartrate and reacting compound
(10) L-tartrate with NaHCO.sub.3 in dichloromethane to provide
purified compound (10). The corresponding salt formation and
neutralization procedures are described below.
[0288] Crude compound 10 and 2-propanol are stirred at
15-30.degree. C. for about 15 minutes until a solution is obtained.
L-Tartaric acid and methanol are stirred at 15-30.degree. C. for
about 1 hour until a solution is obtained. The L-tartaric acid
solution is then added to the solution of crude compound 10 and the
reaction mixture is stirred at 15-30.degree. c. for about 1 hour.
n-Heptane is then added to the reaction mixture and the resulting
mixture is stirred at 15-30.degree. C. for about 1 hour. The
reaction mixture is filtered and the wet cake is washed with
n-heptane and dried to afford the corresponding L-tartaric acid
salt of compound 10.
[0289] Dichloromethane (DCM) and L-tartaric acid salt of compound
10 are charged to a reactor at ambient temperature, and aqueous
NaHCO.sub.3 solution is charged to the reactor while maintaining
the reaction mixture at no more than 30.degree. C. The reaction
mixture is stirred at 15-30.degree. C. for about 30 minutes and the
phases are separated. The organic phase is concentrated under
reduced pressure until the distillation stops. The distillation
residue is then treated with ethanol (EtOH) and the resulting
solution of compound 10 in ethanol (EtOH) is directly used in the
subsequent reaction without further purification.
Step 9. Synthesis of
1-{[4-({(tert-butoxycarbonyl)[(1R,2S)-2-phenylcyclopropyl]amino}methyl)-4-
-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid
(11)
##STR00017##
[0291] Benzyl
1-{[4-({(tert-butoxycarbonyl)[(1R,2S)-2-phenylcyclopropyl]amino}methyl)-4-
-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylate (10)
(449.10 g, 778.65 mmol) was dissolved in ethanol (1570 mL). The
solution was concentrated in vacuo with a bath temperature at
40.degree. C. The residue was again dissolved in ethanol (1570 mL)
and the solution was concentrated using in vacuo with bath
temperature at 40.degree. C. To the residue was added a solution of
potassium hydroxide (89.9 g, 1604 mmol) in ethanol (1570 mL) and
water (224.6 mL). The mixture was then heated in a bath at
40.degree. C. HPLC indicated the reaction was complete (PCT 0.5%)
after 8 hours.
[0292] A vacuum was applied to remove ethanol, then water was added
(2000 mL), the mixture concentrated down, and then the process was
repeated one more time to yield crude product. Water (1570 mL),
2-methoxy-2-methylpropane (2246 mL) and sodium chloride (200.0 mL)
were added to the crude product. The organic layer was then
collected, and concentrated. The residue was re-dissolved in water
(2000 mL), and then concentrated to dryness.
[0293] The residue was re-dissolved in water (2000 mL) and the
solution was washed again with 2-methoxy-2-methylpropane (2246 mL).
The repeated washing with MTBE was performed until the benzyl
alcohol was less than 0.5% in aqueous layer. The aqueous solution
was then cooled in an ice bath before being treated dropwise with
an aqueous HCl solution, made from the concentrated hydrochloric
acid (conc. HCl, 95.0 g, 951 mmol) and water (450.0 g), until pH
5.
[0294] The mixture was extracted with methylene chloride (3000
mL.times.2) twice. The combined DCM layers were concentrated to
give the desired product (11) as a white solid, which was used
directly in the next step. LC-MS calculated for
C.sub.28H.sub.42N.sub.2O.sub.5 [M+H].sup.+ m/z: 487.3; found 487.3.
41 NMR (400 MHz, CD.sub.3CN) .delta. 7.29 (t, J=7.5 Hz, 2H), 7.17
(dd, J=24.1, 7.3 Hz, 3H), 3.53 (d, J=14.4 Hz, 1H), 3.34-3.14 (m,
5H), 3.01-2.73 (m, 7H), 2.43-2.36 (m, 2H), 2.21-1.82 (m, 7H),
1.79-1.58 (m, 4H), 1.38 (s, 9H), 1.23 (q, J=6.5 Hz, 1H).
Step 10. Synthesis of
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate) (12)
##STR00018##
[0295] compound 1 di-tosylate salt
[0296]
1-{[4-({(tert-Butoxycarbonyl)[(1R,2S)-2-phenylcyclopropyl]amino}met-
hyl)-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic
acid (11) (370.0 g, 722.4 mmol) was dissolved in tetrahydrofuran
(2000.0 mL). To the solution was added p-toluenesulfonic acid
monohydrate (300.0 g, 1577 mmol). The mixture was heated to
55-60.degree. C. In 14 hours, HPLC indicated the reaction was
complete (SM<1%). To the mixture while heating was added
2-methoxy-2-methylpropane (4000 mL) through an addition funnel. The
reaction mixture was kept stirring for 6 hours at 55.degree.
C.-60.degree. C. before disconnection of the heat. The mixture was
cooled down to room temperature and stirred overnight. Solid
product was collected by filtration and the cake was washed with
2-methoxy-2-methylpropane (1000 mL) twice, and dried on the filter
overnight. The material
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate) (12) also known as
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid ditosylate salt was
used directly for recrystallization.
Step 11. Crystalline Form I of
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piper-
idin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate (Compound 1 di-tosylate salt, Form
I)
[0297]
1-{[4-(Methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl-
)piperidin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate)
[0298] (12) (532.9 g, 729.1 mmol) was mixed with 2-butanone (7223
mL). The mixture was heated to 55.degree. C. (internal temperature
set) to become a clear solution. The hot solution was polish
filtered through an inline filter, and the clear solution was
distilled off under vacuum to about 4 L volume while being heated
at 55.degree. C. (internal temperature set). To the solution was
added heptane (4676 mL) while stirring. After the addition, the
mixture was kept at 55.degree. C. (internal temperature set) for 4
hours, then allowed to cool to room temperature. The mixture was
stirred overnight. The solid was filtered and washed with a mixture
of heptane (1000.0 mL) and 2-butanone (1000.0 mL). The
recrystallized product
1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}meth-
yl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid
bis(4-methylbenzenesulfonate) (12) was dried on the filter
overnight, and then under high vacuum at 50.degree. C. overnight to
give pure product. LC-MS calculated for
C.sub.37H.sub.50N.sub.2O.sub.9S.sub.2 [M+H].sup.+ m/z: 387.2; found
387.2. .sup.1H NMR (400 MHz, MeOD) .delta. 7.73 (d, J=8.2 Hz, 4H),
7.34-7.19 (m, 7H), 7.15 (d, J=7.2 Hz, 2H), 3.70-3.51 (m, 4H), 3.43
(d, J=18.4 Hz, 7H), 3.36-3.22 (m, 3H), 3.13-2.97 (m, 1H), 2.67-2.50
(m, 3H), 2.38 (s, 6H), 2.21 (q, J=9.5, 8.6 Hz, 2H), 2.05 (dt,
J=28.5, 11.6 Hz, 2H), 1.94-1.78 (m, 1H), 1.66-1.55 (m, 1H), 1.32
(d, J=8.0 Hz, 2H), 0.92 (t, J=6.8 Hz, 1H).
Example 7
[0299] Preparation of Crystalline Forms
[0300] Form HI of Compound 1 di-tosylate salt was prepared during
the process of drying a wet sample of Compound 1 di-tosylate salt,
Form I, under ambient conditions. Form I slowly absorbed
atmospheric moisture and gradually changed to crystalline Form HI.
Under storage conditions of 25.degree. C./60% RH and 40.degree.
C./75% RH, Form I was also converted to Form HI. Form HI can also
be generated by purging humidified air (e.g., 60-85% RH) through
Form I solid.
[0301] Form HII was prepared by slurring of Form I in water for 3
days at room temperature. The resulted suspension was filtered. The
residual solid was collected and air dried for 5-7 days at ambient
condition.
[0302] Form HIII was prepared by drying Form HI on Vapor Sorption
Analyzer (TA Instruments VTI-SA.sup.+) at 40.degree. C. with 0% RH
N.sub.2 for 3 h and then exposing it to humidity at about 30-50% RH
at 25.degree. C. for 1 day. Form HIII can change to Form HI when it
is further exposed to high humidity at about 60-85% RH.Form DH was
prepared by drying Form HI on Vapor Sorption Analyzer (TA
Instruments VTI-SA.sup.+) at 25.degree. C. with 0% RH N.sub.2 for 2
days. When Form DH is exposed to humidity, it can absorb water and
change to Form HIII at about 30-50% RH or to Form HI at high
humidity around 60-85% RH.
[0303] Various modifications of the invention, in addition to those
described herein, will be apparent to those skilled in the art from
the foregoing description. Such modifications are also intended to
fall within the scope of the appended claims. Each reference,
including all patent, patent applications, and publications, cited
in the present application is incorporated herein by reference in
its entirety.
* * * * *